US5562909A - Phosphazene polyelectrolytes as immunoadjuvants - Google Patents

Phosphazene polyelectrolytes as immunoadjuvants Download PDF

Info

Publication number
US5562909A
US5562909A US08/090,841 US9084193A US5562909A US 5562909 A US5562909 A US 5562909A US 9084193 A US9084193 A US 9084193A US 5562909 A US5562909 A US 5562909A
Authority
US
United States
Prior art keywords
phosphazene
polymer
poly
carboxylatophenoxy
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/090,841
Inventor
Harry R. Allcock
Alexander K. Andrianov
Robert S. Langer
Karyn B. Visscher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
Virus Research Institute Inc
Massachusetts Institute of Technology
Original Assignee
Penn State Research Foundation
Virus Research Institute Inc
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation, Virus Research Institute Inc, Massachusetts Institute of Technology filed Critical Penn State Research Foundation
Priority to US08/090,841 priority Critical patent/US5562909A/en
Assigned to MASSACHUSETTS INSTITUTE OF TECHNOLOGY reassignment MASSACHUSETTS INSTITUTE OF TECHNOLOGY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LANGER, ROBERT S.
Assigned to VIRUS RESEARCH INSTITUTE, INC. reassignment VIRUS RESEARCH INSTITUTE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANDRIANOV, ALEXANDER K., JENKINS, SHARON A., PAYNE, LENDON G., ROBERTS, BRYAN E.
Priority to US08/147,781 priority patent/US5529777A/en
Assigned to PENN STATE RESEARCH FOUNDATION reassignment PENN STATE RESEARCH FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALLCOCK, HARRY R., VISSCHER, KARYN B.
Priority to EP94923378A priority patent/EP0710117B1/en
Priority to AU73261/94A priority patent/AU691824B2/en
Priority to JP7504624A priority patent/JPH09500629A/en
Priority to PT94923378T priority patent/PT710117E/en
Priority to DK94923378T priority patent/DK0710117T3/en
Priority to KR1019960700227A priority patent/KR100352336B1/en
Priority to DE69428795T priority patent/DE69428795T2/en
Priority to BR9407051A priority patent/BR9407051A/en
Priority to ES94923378T priority patent/ES2166376T3/en
Priority to NZ269396A priority patent/NZ269396A/en
Priority to SG1996007424A priority patent/SG46659A1/en
Priority to CNB94193067XA priority patent/CN1134265C/en
Priority to CA2166208A priority patent/CA2166208C/en
Priority to AT94923378T priority patent/ATE207505T1/en
Priority to PCT/US1994/007665 priority patent/WO1995002415A1/en
Priority to PCT/US1994/007749 priority patent/WO1995002416A1/en
Priority to NZ269411A priority patent/NZ269411A/en
Priority to US08/273,285 priority patent/US5494673A/en
Priority to BR9407397A priority patent/BR9407397A/en
Priority to EP94923417A priority patent/EP0792161A4/en
Priority to CA002167081A priority patent/CA2167081A1/en
Priority to JP7504650A priority patent/JPH09500132A/en
Priority to KR1019960700228A priority patent/KR100353496B1/en
Priority to AU73286/94A priority patent/AU690567B2/en
Priority to CN94193066A priority patent/CN1128953A/en
Priority to PCT/US1994/007710 priority patent/WO1995002628A1/en
Assigned to SILICON VALLEY BANK reassignment SILICON VALLEY BANK SECURITY AGREEMENT Assignors: VIRUS RESEARCH INSTITUTE, INC.
Publication of US5562909A publication Critical patent/US5562909A/en
Application granted granted Critical
Assigned to VIRUS RESEARCH INSTITUTE, INC. reassignment VIRUS RESEARCH INSTITUTE, INC. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SILICON VALLEY BANK
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/02Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing phosphorus
    • C08G79/025Polyphosphazenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This application is in the area of polymers for biomedical applications, and in particular describes polymers that can be used as immunoadjuvants.
  • antigens stimulate the production of antibodies in animals and confer protection against subsequent infection. However, some antigens are unable to stimulate an effective immune response.
  • the immunogenicity of a relatively weak antigen is often enhanced by the simultaneous administration of the antigen with an adjuvant, a substance that is not immunogenic when administered alone, but will induce a state of mucosal and/or systemic immunity when combined with the antigen.
  • adjuvants such as mineral oil emulsions or aluminum hydroxide, form an antigen depot at the site of injection that slowly releases antigen.
  • Freund's Complete Adjuvant contains a suspension of heat-killed Mycobacterium tuberculosis in mineral oil containing a surfactant and causes granulomatous lesions in animals at the site of immunization. Freund's adjuvant may also cause the recipient of a vaccine to test positive for tuberculosis.
  • PAA polyacrylic acid
  • CP-AA-VPD poly-2-methyl-5-vinyl pyridine
  • PMVP poly-4-vinyl-N-ethylpyridinium bromide
  • PVP-R 2 poly-4-vinyl-N-ethylpyridinium bromide
  • a non-toxic adjuvant or carrier having the ability to stimulate an immune response to non-antigenic or weakly antigenic molecules would be useful in the development and administration of vaccines.
  • a synthetic, water-soluble polyphosphazene is disclosed for use as an adjuvant.
  • the phosphazene is a polyelectrolyte that is biodegradable and that exhibits minimal toxicity when administered to animals, such as humans.
  • the polymeric adjuvant is an poly(organophosphazene) with (i) ionized or ionizable pendant groups that contain, for example, carboxylic acid, sulfonic acid, or hydroxyl moieties, and (ii) pendant groups that are susceptible to hydrolysis under the conditions of use, to impart biodegradability to the polymer.
  • Suitable hydrolyzable groups include, for example, chlorine, amino acid, amino acid ester, imidazole, glycerol, and glucosyl.
  • polyphosphazenes that are useful as immunoadjuvants are poly[di(carboxylatophenoxy)phosphazene-co-di(glycinato)phosphazene-co-(carboxylatophenoxy) (glycinato)phosphazene] and poly[di(carboxylatophenoxy)phosphazene-co-di(chloro)phosphazene-co-(carboxylatophenoxy)(chloro)phosphazene].
  • a vaccine composition is prepared by either mixing or conjugating the polymer adjuvant with an antigen prior to administration. Alternatively, the polymer and antigen can be administered separately to the same site.
  • the polymer When cross-linked with a multivalent ion, the polymer becomes less soluble, resulting in slower release of the polymer from the site of administration.
  • amino acid refers to both natural and synthetic amino acids, and includes, but is not limited to alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaoyl, lysinyl, argininyl, and histidinyl.
  • amino acid ester refers to the aliphatic, aryl or heteroaromatic carboxylic acid ester of a natural or synthetic amino acid.
  • alkyl refers to a saturated straight, branched, or cyclic hydrocarbon, or a combination thereof, typically of C 1 to C 20 , and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, heptyl, octyl, nonyl, and decyl.
  • alkyl or dialkylamino refers to an amino group that has one or two alkyl substituents, respectively.
  • alkenyl and alkynyl refers to a C 2 to C 20 straight or branched hydrocarbon with at least one double or triple bond, respectively.
  • aryl refers to phenyl or substituted phenyl, wherein the substituent is halo, alkyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, alkoxyalkyl, methylenedioxy, cyano, C(O)(lower alkyl), --CO 2 H, --SO 3 H, --PO 3 H, --CO 2 alkyl, amide, amino, alkylamino and dialkylamino, and wherein the aryl group can have up to 3 substituents.
  • aliphatic refers to hydrocarbon, typically of C l to C 20 , that can contain one or a combination of alkyl, alkenyl, or alkynyl moieties, and which can be straight, branched, or cyclic, or a combination thereof.
  • halo includes fluoro, chloro, bromo, and iodo.
  • aralkyl refers to an aryl group with an alkyl substituent.
  • alkaryl refers to an alkyl group that has an aryl substituent, including benzyl, substituted benzyl, phenethyl or substituted phenethyl, wherein the substituents are as defined above for aryl groups.
  • heteroaryl or heteroaromatic refers to an aromatic moiety that includes at least one sulfur, oxygen, or nitrogen in the aromatic ring, and that can be optionally substituted as described above for aryl groups.
  • Nonlimiting examples are furyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbozolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, pyrazolyl, quinazolinyl, pyridazinyl
  • pharmaceutically acceptable cation refers to an organic or inorganic moiety that carries a positive charge and that can be administered as a countercation in a phosphazene polyelectrolyte.
  • heteroalkyl refers to a alkyl group that includes a heteroatom such as oxygen, sulfur, or nitrogen (with valence completed by hydrogen or oxygen) in the carbon chain or terminating the carbon chain.
  • a synthetic polymer is provided for use as an immunoadjuvant.
  • the polymer adjuvant is a polyphosphazene that is at least partially soluble in water (typically to an extent of at least 0.001% by weight), an aqueous buffered salt solution, or aqueous alcohol solution.
  • the polyphosphazene preferably contains charged side groups, either in the form of an acid or base that is in equilibrium with its counter ion, or in the form of an ionic salt thereof.
  • the polymer is preferably biodegradable and exhibits minimal toxicity when administered to animals, including humans.
  • Polyphosphazenes are polymers with backbones consisting of alternating phosphorus and nitrogen, separated by alternating single and double bonds. Each phosphorous atom is covalently bonded to two pendant groups ("R").
  • R pendant groups
  • the repeat unit in polyphosphazenes has the following general formula: ##STR1## wherein n is an integer.
  • R can be any of a wide variety of moieties that can vary within the polymer, including but not limited to aliphatic, aryl, aralkyl, alkaryl, carboxylic acid, heteroaromatic, carbohydrates, including glucose, heteroalkyl, halogen, (aliphatic)amino- including alkylamino-, heteroaralkyl, di(aliphatic)amino- including dialkylamino-, arylamino-, diarylamino-, alkylarylamino-, -oxyaryl including but not limited to -oxyphenylCO 2 H, -oxyphenylSO 3 H, -oxyphenylhydroxyl and -oxyphenylPO 3 H; -oxyaliphatic including -oxyalkyl, -oxy(aliphatic)CO 2 H, -oxy(aliphatic)SO 3 H, -oxy(aliphatic)PO 3 H, and -oxy(aliphatic)hydroxyl, including -oxy(alkyl
  • the groups will vary randomly throughout the polymer, and the polyphosphazene is thus a random copolymer.
  • Phosphorous can be bound to two like groups, or two different groups.
  • Polyphosphazenes with two or more types of pendant groups can be produced by reacting poly(dichlorophosphazene) with the desired nucleophile or nucleophiles in a desired ratio.
  • the resulting ratio of pendant groups in the polyphosphazene will be determined by a number of factors, including the ratio of starting materials used to produce the polymer, the temperature at which the nucleophilic substitution reaction is carried out, and the solvent system used. While it is very difficult to determine the exact substitution pattern of the groups in the resulting polymer, the ratio of groups in the polymer can be easily determined by one skilled in the art.
  • the immunoadjuvant is a biodegradable polyphosphazene of the formula: ##STR2## wherein A and B can vary independently in the polymer, and can be: (i) a group that is susceptible to hydrolysis under the conditions of use, including but not limited to chlorine, amino acid, amino acid ester (bound through the amino group), imidazole, glycerol, or glucosyl; or
  • a group that is not susceptible to hydrolysis under the conditions of use including, but not limited to an aliphatic, aryl, aralkyl, alkaryl, carboxylic acid, heteroaromatic, heteroalkyl, (aliphatic)amino- including alkylamino-, heteroaralkyl, di(aliphatic)amino- including dialkylamino-, arylamino-, diarylamino-, alkylarylamino-, -oxyaryl including but not limited to -oxyphenylCO 2 H, -oxyphenylSO 3 H, -oxyphenylhydroxyl and -oxyphenylPO 3 H; -oxyaliphatic including -oxyalkyl, -oxy(aliphatic)CO 2 H, -oxy(aliphatic)SO 3 H, -oxy(aliphatic)PO 3 H, and -oxy(aliphatic)hydroxyl, including -oxy(alkyl)hydroxyl; -oxyalkaryl,
  • polymer contains at least one percent or more, preferably 10 percent or more, and more preferably 80 to 90 percent or more, but less than 100%, of repeating units that are not susceptible to hydrolysis under the conditions of use, and
  • n is an integer of 4 or more, and preferably between 10 and 20,000.
  • certain groups such as heteroaromatic groups other than imidazole, hydrolyze at an extremely slow rate under neutral aqueous conditions, such as that found in the blood, and therefore are typically considered nonhydrolyzable groups for purposes herein.
  • the rate of hydrolysis of normally nonhydrolyzable groups can increase to the point that the biodegradation properties of the polymer can be affected.
  • One of ordinary skill in the art using well known techniques can easily determine whether pendant groups hydrolyze at a significant rate under the conditions of use.
  • One of ordinary skill in the art can also determine the rate of hydrolysis of the polyphosphazenes of diverse structures as described herein, and will be able to select that polyphosphazene that provides the desired biodegradation profile for the targeted use.
  • the degree of hydrolytic degradability of the polymer will be a function of the percentage of pendant groups susceptible to hydrolysis and the rate of hydrolysis of the hydrolyzable groups.
  • the hydrolyzable groups are replaced by hydroxyl groups in aqueous environments to provide P--OH bonds that impart hydrolytic instability to the polymer.
  • the immunoadjuvant is: (i) a nonbiodegradable polyphosphazene wherein none, or virtually none, of the pendant groups in the polymer are susceptible to hydrolysis under the conditions of use, or (ii) a completely biodegradable polyphosphazene wherein all of the groups are susceptible to hydrolysis under the conditions of use (for example, poly[di(glycinato)phosphazene]).
  • Phosphazene polyelectrolytes are defined herein as polyphosphazenes that contain ionized or ionizable pendant groups that render the polyphosphazene anionic, cationic or amphophilic.
  • the ionic groups can be in the form of a salt, or, alternatively, an acid or base that is or can be at least partially dissociated. Any pharmaceutically acceptable monovalent cation can be used as counterion of the salt, including but not limited to sodium, potassium, and ammonium.
  • the phosphazene polyelectrolytes can also contain non-ionic side groups.
  • the phosphazene polyelectrolyte can be biodegradable or nonbiodegradable under the conditions of use.
  • the ionized or ionizable pendant groups are preferably not susceptible to hydrolysis under the conditions of use.
  • a preferred phosphazene polyelectrolyte immunoadjuvant contains pendant groups that include carboxylic acid, sulfonic acid, or hydroxyl moieties. While the acidic groups are usually on nonhydrolyzable pendant groups, they can alternatively, or in combination, also be positioned on hydrolyzable groups.
  • An example of a phosphazene polyelectrolyte having carboxylic acid groups as side chains is shown in the following formula: ##STR3## wherein n is an integer, preferably an integer between 10 and 10,000.
  • This polymer has the chemical name poly[di(carboxylatophenoxy)phosphazene]or, alternatively, poly[bis(carboxylatophenoxy)phosphazene](PCPP).
  • the phosphazene polyelectrolyte is preferably biodegradable to prevent eventual deposition and accumulation of polymer molecules at distant sites in the body, such as the spleen.
  • biodegradable means a polymer that degrades within a period that is acceptable in the desired application, typically less than about five years and most preferably less than about one year, once exposed to a physiological solution of pH 6-8 at a temperature of approximately 25° C. -37° C.
  • the polymer is a poly(organophosphazene) that includes pendant groups that include carboxylic acid moieties that do not hydrolyze under the conditions of use and pendant groups that are susceptible to hydrolysis under the conditions of use.
  • preferred phosphazene polyelectrolytes with hydrolysis-sensitive groups are poly[di(carboxylatophenoxy)phosphazene-co-di(amino acid)phosphazene-co(carboxylatophenoxy)(amino acid)phosphazene], specifically including poly[di(carboxylatophenoxy)phosphazene-co-di(glycinato)phosphazene-co(carboxylatophenoxy)(glycinato)phosphazene], and poly[di(carboxylatophenoxy)phosphazene-co-di(chloro)phosphazene-co(carboxylatophenoxy)(chloro)phosphazene].
  • the toxicity of the polyphosphazene can be determined using cell culture experiments well known to those skilled in the art. For example, toxicity of poly[di(carboxylatophenoxy)phosphazene] was determined in cell culture by coating cell culture dishes with the poly[di(carboxylatophenoxy)phosphazene]. Chicken embryo fibroblasts were then seeded onto the coated petri dishes. Three days after seeding the chicken embryo fibroblasts, the cells had become flattened and spindles formed. Under phase contrast microscopy, mitotic figures were observed. These observations provide evidence of the non-toxicity of poly[di(carboxylatophenoxy)phosphazene] to replicating cells.
  • Crosslinked polyphosphazenes for use as immunoadjuvants can be prepared by combining a phosphazene polyelectrolyte with a metal multivalent cation such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, or cadmium.
  • a metal multivalent cation such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, or cadmium.
  • Polyphosphazenes including phosphazene polyelectrolytes, can be prepared by a macromolecular nucleophilic substitution reaction of poly(dichlorophosphazene) with a wide range of chemical reagents or mixture of reagents in accordance with methods known to those skilled in the art.
  • the phosphazene polyelectrolytes are made by reacting the poly(dichlorophosphazene) with an appropriate nucleophile or nucleophiles that displace chlorine.
  • Desired proportions of hydrolyzable to non-hydrolyzable side chains in the polymer can be obtained by adjusting the quantity of the corresponding nucleophiles that are reacted with poly(dichlorophosphazene) and the reaction conditions as necessary.
  • Preferred polyphosphazenes for immunoadjuvant activity have a molecular weight of over 1,000.
  • poly[(carboxylatophenoxy)(glycinato)phosphazene] (PC-G1PP) is prepared by the nucleophilic substitution reaction of the chlorine atoms of the poly(dichlorophosphazene) with propyl p-hydroxybenzoate and ethyl glycinato hydrochloride (PC-G1PP synthesis).
  • the poly[(aryloxy)(glycinato)phosphazene] ester thus obtained is then hydrolyzed to the corresponding poly(carboxylic acid).
  • Other polyphosphazenes can be prepared as described by Allcock, H. R.; et al., Inorg. Chem. 11, 2584 (1972); Allcock, H.
  • the antigen can be derived from a cell, bacteria, or virus particle, or portion thereof.
  • antigen may be a protein, peptide, polysaccharide, glycoprotein, glycolipid, nucleic acid, or combination thereof, which elicits an immunogenic response in an animal, for example, a mammal, bird, or fish.
  • the immunogenic response can be humoral or cell-mediated.
  • the material to which the immunogenic response is to be directed is poorly antigenic, it may be conjugated to a carrier such as albumin or to a hapten, using standard covalent binding techniques, for example, with one of the several commercially available reagent kits.
  • the polymer is used to deliver nucleic acid which encodes antigen to a mucosal surface where the nucleic acid is expressed.
  • antigens examples include viral proteins such as influenza proteins, human immunodeficiency virus (HIV) proteins, and hepatitis B proteins, and bacterial proteins and lipopolysaccharides such as gram negative bacterial cell walls and Neisseria gonorrhea proteins.
  • viral proteins such as influenza proteins, human immunodeficiency virus (HIV) proteins, and hepatitis B proteins
  • bacterial proteins and lipopolysaccharides such as gram negative bacterial cell walls and Neisseria gonorrhea proteins.
  • An immunogenic composition, or vaccine is prepared by combining the polymer adjuvant with an antigen. Approximately 0.5-0.0001 parts of antigen is added to one part polymer, preferably by stirring a solution of polymer and antigen until a solution or suspension is obtained, preferably for 10 minutes or more at 25° C.
  • the polymer is preferably combined with the antigen using a method dispersing the antigen uniformly throughout the adjuvant. Methods for liquifying the polymer include dissolving the polymer in an aqueous-based solvent, preferably having a pH range of between 7.1 and 7.7, and melting the polymer. The latter is useful only when the antigen is stable at the polymer melting temperature.
  • the antigen is then mixed with the polymer.
  • the polymer and the antigen, in solid form, for example, when the antigen is lyophilized, can also be physically mixed together, for example, by compression molding.
  • the polymer can also be used to encapsulate the antigen, for example, using the method of U.S. Pat. No. 5,149,543 to Cohen, et al., the teachings of which are incorporated herein, or by spray drying a solution of polymer and antigen.
  • microspheres containing the antigen and adjuvant can be prepared by simply mixing the components in an aqueous solution, and then coagulating the polymer together with the substance by mechanical forces to form a microparticle.
  • the microparticle can be stabilized, if necessary or desired, using electrolytes, pH changes, organic solvents, heat or frost to form polymer matrices encapsulating biological material.
  • approximately one part of polymer is dissolved in 10 parts 3% Na 2 CO 3 aqueous solution while stirring, then 10 to 90 parts phosphate buffer pH 7.4 is slowly added.
  • the polymer can also be covalently conjugated with the antigen to create a water-soluble conjugate in accordance with methods well-known to those skilled in the art, usually by covalent linkage between an amino or carboxyl group on the antigen and one of the ionizable side groups on the polymer.
  • the polymer is cross-linked with a multivalent ion, preferably using an aqueous solution containing multivalent ions of the opposite charge to those of the charged side groups of the polyphosphazene, such as multivalent cations if the polymer has acidic side groups or multivalent anions if the polymer has basic side groups.
  • the polymers are cross-linked by di and trivalent metal ions such as calcium, copper, aluminum, magnesium, strontium, barium, tin, zinc, and iron, organic cations such as poly(amino acid)s, or other polymers such as poly(ethyleneimine), poly(vinylamine) and polysaccharides.
  • di and trivalent metal ions such as calcium, copper, aluminum, magnesium, strontium, barium, tin, zinc, and iron
  • organic cations such as poly(amino acid)s
  • other polymers such as poly(ethyleneimine), poly(vinylamine) and polysaccharides.
  • the immunogenic vaccine composition can contain other physiologically acceptable ingredients such as water, saline or a mineral oil such as DrakeolTM, MarkolTM, and squalene to form an emulsion
  • the immunogenic composition can be administered as a vaccine by any method known to those skilled in the art that elicits an immune response, including parenterally, orally, or by transmembrane or transmucosal administration.
  • the vaccine is administered parenterally (intravenously, intramuscularly, subcutaneously, intraperitoneally, etc.), and preferably subcutaneously.
  • routes of delivery to mucosal surfaces are intranasal (or generally, the nasal associated lymphoid tissue), respiratory, vaginal, and rectal.
  • the dosage is determined by the antigen loading and by standard techniques for determining dosage and schedules for administration for each antigen, based on titer of antibody elicited by the polymer-antigen administration, as demonstrated by the following examples.
  • the polymer-antigen mixture is administered simultaneously
  • the polymer and antigen are administered separately to the same or nearby site.
  • the polymer serves to attract cells of the immune system to the site, where they process the antigen.
  • polyphosphazene adjuvants and methods of synthesis will be further understood by reference to the following non-limiting examples.
  • Poly[(carboxylatophenoxy)(glycinato)phosphazene] was prepared as follows. Poly(dichlorophosphazene) (5.0, 0.0425 moles) was dissolved in 300 ml tetrahydrofuran (THF). The sodium salt of propyl p-hydroxybenzoate (prepared by reacting propyl hydroxybenzoate (30.6 g, 0.17 moles) with 60% sodium hydride (6.12, 0.15 moles) in THF) was added dropwise to the dissolved polymer. After addition of the sodium salt, the reaction mixture was stirred at reflux for 2 days and monitored by 31 P NMR.
  • THF tetrahydrofuran
  • Ethyl glycinate hydrochloride (23.63 g, 0.17 moles) was suspended in 50 ml toluene containing triethylamine (23.69, 0.17 moles) and refluxed for 3.5 hours. The reaction mixture was cooled in an ice bath and triethylamine hydrochloride precipitated from the solution. The solution was filtered and added to the polymer mixture at 0° C. The reaction mixture was allowed to warm to room temperature and stirred for 2 days. The polymer was purified by repeated precipitations into 100% ethanol.
  • the resulting polymer (0.5 g, 1.33 mmol) was dissolved in dry THF (20 ml). The solution was added slowly to a mixture of potassium tert-butoxide and water in dry THF. For the first 5 minutes, the mixture was cooled to 0° C.; it was then stirred at room temperature for 40 hours. A large excess of ice water (300 ml) was added, and the solution was concentrated by evaporation. The polymer was isolated by acidification of the solution with hydrochloric acid to pH 5.5. The conditions of reactions and weight average molecular weights of obtained polymers measured by gel permeation chromatography in water is shown in Table 1 below.
  • Poly[di(carboxylatophenoxy)phosphazene] was prepared by chemical modification of poly(dichlorophosphazene) with the sodium salt of propyl p-hydroxybenzoate, followed by hydrolysis of ester groups to carboxylic acid as described in Allcock, H. R. & Kwon, S. (1989) Macromolecules 22, 75-79, the teachings of which are incorporated herein.
  • Poly[(carboxylatophenoxy)(chloro)phosphazene] was prepared as follows. Poly[di(chloro)phosphazene] (5.0 g, 0.0425 moles) was dissolved in 300 mL tetrahydrofuran (THF). The sodium salt of propyl p-hydroxybenzoate, prepared by reacting propyl hydroxybenzoate (30.6 g, 0.17 moles) with 60 % sodium hydride (6.12 g, 015 moles) in THF, was added dropwise to the dissolved polymer. After addition of the sodium salt, the reaction mixture was stirred at reflux for 2 days and monitored by 31 P NMR. The polymer was purified by repeated precipitations into water, ethanol and hexane.
  • THF tetrahydrofuran
  • Poly[(propylhydroxybenzoate)(chloro)phosphazene] (2.0 g) was dissolved in 200 mL dry THF. 20 g potassium tert-butoxide was dissolved in 200 mL THF. The basic solution was cooled to 0° C. Water (1 mL) was added to the butoxide/THF solution and stirred for 5 minutes. The polymer solution then was added dropwise to the aqueous base. The reaction mixture was warmed to room temperature and stirred for 40 hours. After 40 hours, the reaction mixture was poured over an ice-water mixture and the THF was allowed to evaporate. The aqueous solution was then dialyzed against water for 2 days. After dialysis was complete, the dialysate was acidified with HCl and the resultant white precipitate, poly[(carboxylatophenoxy)(chloro)phosphazene], was washed with water and filtered from the solution.
  • the molecular weight of polyphosphazenes was determined by a Perkin-Elmer Series 10 liquid chromatograph with refractive index and a refractive index detector by using an Ultragel 2000 column (Waters Chromatography Division, Millipore Corporation, Cidra, Puerto Rico). 13 mM Hepes buffered saline solution (pH 7.4) was used as an eluant. Chromatograms were processed by GPC 5 and CHROM 2 software (Perkin-Elmer) to calculate the weight-average and number-average molecular weights using polyacrylic acid as a standard. The decline in polymer molecular weight over time is shown in Table 2.
  • Antibody titers were determined in female BALB/c mice, age 7 to 8 weeks, that had been inoculated with tetanus toxoid admixed with a polyphosphazene adjuvant.
  • An immunogenic composition containing tetanus toxoid in polyphosphazene was prepared as follows. 100 mg of poly[di(carboxylatophenoxy)phosphazene] was dissolved in 1 ml Na 2 CO 3 and 1 ml phosphate buffered saline (PBS), pH 7.2 was added. 1.4 ml tetanus toxoid (2.2 mg/ml or 1000 LF/ml, Connaught Laboratories, Inc., Swiftwater, Pa.) was added with 0.6 ml containing 0.025% Brij solution (10 ⁇ l of 10% Brij 58, Sigma Chemical Co., St. Louis, Mo.) to the polymer.
  • PBS phosphate buffered saline
  • mice Groups of five mice were immunized subcutaneously with a single dose of 25 ⁇ g tetanus toxoid admixed with dilutions containing 0.5% polyphosphazene, 0.05% polyphosphazene, or 0.005% polyphosphazene in dH 20 .
  • a separate group of mice was immunized with a single subcutaneous dose of 25 ⁇ g of tetanus toxoid in complete Freund's adjuvant (SIGMA, St. Louis, Mo.). Blood samples were taken from the retroorbital sinus of CO 2 anaesthetized mice and analyzed by an ELISA immunoassay for anti-tetanus toxoid IgG.
  • Antibody titers were determined in female BALB/c mice, age 7 to 8 weeks, that had been inoculated with either influenza or tetanus toxoid admixed with the polyphosphazene adjuvant described in Example 5.
  • Two immunogenic compositions one containing tetanus toxoid in polyphosphazene and the other containing influenza in polyphosphazene, were prepared as follows. 100 mg of poly[di(carboxylatophenoxy) phosphazene] was dissolved in 1 ml Na 2 CO 3 and 1 ml phosphate buffered saline (PBS), pH 7.6 was added.
  • PBS phosphate buffered saline
  • tetanus toxoid (2.2 mg/ml) (Connaught Laboratories, Swiftwater, Pa.) or influenza (Influenza Branch, Center for Disease Control, Atlanta, Ga.) was diluted 1:10 in water and the appropriate volume of each was admixed with either 0.1% or 0.05% polyphosphazene.
  • mice Groups of three mice were immunized subcutaneously with a single dose of each immunogenic composition. Blood samples were taken from the retroorbital sinus of CO 2 anaesthetized mice after 21 days after inoculation and analyzed by an ELISA immunoassay for anti-tetanus toxoid or anti-influenza IgG.
  • influenza immunoassay protocol was performed to determine the influenza titers: 96-well ELISA microtiter plates were coated with influenza cell lysates at 10 ⁇ g/ml in carbonate buffer, pH 9.6, 100 ml per well and incubated 2 hours at 37° C. The plate was washed with 0.05% Tween 20/PBS (Sigma, St. Louis, Mo.) and 100 ⁇ l 12.5% bovine serum albumin/phosphate buffered saline (BSA/PBS) was added to each well as a blocking step. The plate was then incubated 1 hour at 37° C. and washed with 0.05% Tween 20/PBS. 50 ⁇ l 1% BSA/PBS was added to all wells.
  • Tween 20/PBS Sigma, St. Louis, Mo.
  • BSA/PBS bovine serum albumin/phosphate buffered saline
  • Serum samples were diluted to 1:128 by adding 5 ⁇ l serum to 635 ⁇ l % BSA/PBS.
  • 50 ⁇ l of the dilute serum sample to be assayed was added to the first well in a row, a 1:256 dilution. Both positive and negative controls were tested.
  • Two-fold serial dilutions of serum sample were made by removing 50 ⁇ l from the first well in a row and adding the 50 ⁇ l with mixing to the second well; then removing 50 ⁇ l from the second well and adding it to the third well with mixing, and so on down the row, discarding 50 ⁇ l from the final or 12th well.
  • the plates were then incubated 1 hour at 37° C. and the plate washed with 0.05% Tween 20/PBS.
  • OPD solution 0.4 mg/ml solution of 0-phenylenediamine dihydrochloride (Sigma, St. Louis, Mo.) in 0.05 M phosphate-citrate buffer pH 5.0 (1 OPD tablet per 12.5 ml citrate buffer) containing 0.05% hydrogen peroxide (20.8 ⁇ l 30% H 2 O 2 per 12.5 ml citrate buffer)).
  • the color was allowed to develop for 30 minutes, then stopped by addition of 50 ⁇ l 2M H 2 SO 4 / well.
  • the absorbance was read at OD 490 , and the endpoint titer determined by finding the dilution of each serum sample that had an OD 490 greater than or equal to two times the OD 490 of the negative control at the same dilution.
  • TT tetanus toxoid
  • flu tetanus toxoid
  • PP polyphosphazene
  • Influenza Hemagglutination Inhibition Titers after Immunization with Influenza Admixed with a Polyphosphazene Adjuvant were assessed for the following effects:
  • An influenza hemagglutination inhibition antibody assay was performed with heat-inactivated mouse serum that had been incubated for 30 minutes with 10% chicken red blood cells (Spafas, Storrs, Conn.) to remove nonspecific inhibitors. Two-fold dilutions of sera were added to a 96-well microtiter plate and 8 hemagglutination (HA) units of virus suspension in a equal volume were added to each well and incubated at room temperature for 30 minutes. A 0.5% suspension of chicken red blood cells was added to each well and incubated at room temperature for 45-60 minutes.
  • HA hemagglutination
  • Hemagglutination inhibition (HI) titers are expressed in Table 6 below as the reciprocal of the highest dilution that completely inhibits hemagglutination of erythrocytes.
  • Polymer 1 100 mg of poly[di(carboxylatophenoxy) phosphazene] (Polymer 1) was dissolved in 1 ml Na 2 CO 3 and 3 ml of PBS was added to the polymer solution. 100 mg of poly[(carboxylatophenoxy)(glycinato)phosphazene] (Polymer 2) was dissolved in the same solvents.
  • Antibody titers were determined in groups of female BALB/c mice, three mice per group, age 7 to 8 weeks, 21 days after inoculation with 5 ⁇ g influenza admixed with one of each of the polymers.

Abstract

A immunoadjuvant soluble phosphazene polyelectrolyte is disclosed. In one embodiment, the polymeric adjuvant is an poly(organophosphazene) with (i) ionized or ionizable pendant groups that contain, for example, carboxylic acid, sulfonic acid, or hydroxyl moieties, and (ii) pendant groups that are susceptible to hydrolysis under the conditions of use, to impart biodegradability to the polymer.

Description

BACKGROUND OF THE INVENTION
This application is in the area of polymers for biomedical applications, and in particular describes polymers that can be used as immunoadjuvants.
Vaccine Development
A wide variety of antigens stimulate the production of antibodies in animals and confer protection against subsequent infection. However, some antigens are unable to stimulate an effective immune response.
The immunogenicity of a relatively weak antigen is often enhanced by the simultaneous administration of the antigen with an adjuvant, a substance that is not immunogenic when administered alone, but will induce a state of mucosal and/or systemic immunity when combined with the antigen. It has been traditionally thought that adjuvants, such as mineral oil emulsions or aluminum hydroxide, form an antigen depot at the site of injection that slowly releases antigen. Recent studies by Allison and Byars, in: "Vaccines: New Approaches to Immunological Problems":, R. W. Ellis, ed., p. 431, Butterworth-Heinemann, Oxford (1992) indicate that adjuvants enhance the immune response by stimulating specific and sometimes very narrow branches of the immune response by the release of cytokines. Unfortunately, many immunoadjuvants, such as Freund's Complete Adjuvant, are toxic and are therefore only useful for animal research purposes, not human vaccinations. Freund's Complete Adjuvant contains a suspension of heat-killed Mycobacterium tuberculosis in mineral oil containing a surfactant and causes granulomatous lesions in animals at the site of immunization. Freund's adjuvant may also cause the recipient of a vaccine to test positive for tuberculosis. Some synthetic polyelectrolytes have been found to provide immunostimulation when combined with an antigen. For example, the adjuvant activity of polyacrylic acid (PAA), copolymers of acrylic acid and N-vinylpyrrolidone (CP-AA-VPD), poly-2-methyl-5-vinyl pyridine (PMVP), poly-4-vinyl-N-ethylpyridinium bromide (PVP-R2) and similar compounds, when conjugated to an antigen, has been studied by Petrov et. al., Jhurnal Vses. Khim. Ob-va im. D. I. Mendeleeva, 33:22-42 (1988). The immunomodulatory effect of polyelectrolyte complexes containing many of these same polyelectrolytes has also been more recently reviewed by Petrov, et al., Sov. Med. Rev. D. Immunol., 4:1-113 (1992). However, the toxicity and biodegradability of these polymers has not been studied and may prevent use of these polymers as adjuvants for use in humans.
A non-toxic adjuvant or carrier having the ability to stimulate an immune response to non-antigenic or weakly antigenic molecules would be useful in the development and administration of vaccines.
Therefore, it is an object of the present invention to provide an adjuvant that can be safely administered to humans and animals with minimal toxicity.
It is a further object of the present invention to provide an adjuvant that is soluble and biodegradable.
It is a further object of the present invention to provide a vaccine that confers protection against an organism such as the influenza virus or Clostridium tetani bacteria.
It is a further object of the present invention to provide a rapid and efficient method of synthesizing a polymer, such as polyphosphazene, for use as an adjuvant.
SUMMARY OF THE INVENTION
A synthetic, water-soluble polyphosphazene is disclosed for use as an adjuvant. In a preferred embodiment, the phosphazene is a polyelectrolyte that is biodegradable and that exhibits minimal toxicity when administered to animals, such as humans.
In one embodiment, the polymeric adjuvant is an poly(organophosphazene) with (i) ionized or ionizable pendant groups that contain, for example, carboxylic acid, sulfonic acid, or hydroxyl moieties, and (ii) pendant groups that are susceptible to hydrolysis under the conditions of use, to impart biodegradability to the polymer. Suitable hydrolyzable groups include, for example, chlorine, amino acid, amino acid ester, imidazole, glycerol, and glucosyl.
Two examples of polyphosphazenes that are useful as immunoadjuvants are poly[di(carboxylatophenoxy)phosphazene-co-di(glycinato)phosphazene-co-(carboxylatophenoxy) (glycinato)phosphazene] and poly[di(carboxylatophenoxy)phosphazene-co-di(chloro)phosphazene-co-(carboxylatophenoxy)(chloro)phosphazene].
A vaccine composition is prepared by either mixing or conjugating the polymer adjuvant with an antigen prior to administration. Alternatively, the polymer and antigen can be administered separately to the same site.
When cross-linked with a multivalent ion, the polymer becomes less soluble, resulting in slower release of the polymer from the site of administration.
DETAILED DESCRIPTION OF THE INVENTION
The term amino acid, as used herein, refers to both natural and synthetic amino acids, and includes, but is not limited to alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaoyl, lysinyl, argininyl, and histidinyl.
The term amino acid ester refers to the aliphatic, aryl or heteroaromatic carboxylic acid ester of a natural or synthetic amino acid.
The term alkyl, as used herein, refers to a saturated straight, branched, or cyclic hydrocarbon, or a combination thereof, typically of C1 to C20, and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, heptyl, octyl, nonyl, and decyl.
The term (alkyl or dialkyl)amino refers to an amino group that has one or two alkyl substituents, respectively.
The terms alkenyl and alkynyl, as used herein, refers to a C2 to C20 straight or branched hydrocarbon with at least one double or triple bond, respectively.
The term aryl, as used herein, refers to phenyl or substituted phenyl, wherein the substituent is halo, alkyl, alkoxy, alkylthio, haloalkyl, hydroxyalkyl, alkoxyalkyl, methylenedioxy, cyano, C(O)(lower alkyl), --CO2 H, --SO3 H, --PO3 H, --CO2 alkyl, amide, amino, alkylamino and dialkylamino, and wherein the aryl group can have up to 3 substituents.
The term aliphatic refers to hydrocarbon, typically of Cl to C20, that can contain one or a combination of alkyl, alkenyl, or alkynyl moieties, and which can be straight, branched, or cyclic, or a combination thereof.
The term halo, as used herein, includes fluoro, chloro, bromo, and iodo.
The term aralkyl refers to an aryl group with an alkyl substituent.
The term alkaryl refers to an alkyl group that has an aryl substituent, including benzyl, substituted benzyl, phenethyl or substituted phenethyl, wherein the substituents are as defined above for aryl groups.
The term heteroaryl or heteroaromatic, as used herein, refers to an aromatic moiety that includes at least one sulfur, oxygen, or nitrogen in the aromatic ring, and that can be optionally substituted as described above for aryl groups. Nonlimiting examples are furyl, pyridyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbozolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2,4-thiadiazolyl, isooxazolyl, pyrrolyl, pyrazolyl, quinazolinyl, pyridazinyl, pyrazinyl, cinnolinyl, phthalazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl.
The term "pharmaceutically acceptable cation" refers to an organic or inorganic moiety that carries a positive charge and that can be administered as a countercation in a phosphazene polyelectrolyte.
The term heteroalkyl, as used herein, refers to a alkyl group that includes a heteroatom such as oxygen, sulfur, or nitrogen (with valence completed by hydrogen or oxygen) in the carbon chain or terminating the carbon chain.
A synthetic polymer is provided for use as an immunoadjuvant. The polymer adjuvant is a polyphosphazene that is at least partially soluble in water (typically to an extent of at least 0.001% by weight), an aqueous buffered salt solution, or aqueous alcohol solution. The polyphosphazene preferably contains charged side groups, either in the form of an acid or base that is in equilibrium with its counter ion, or in the form of an ionic salt thereof.
The polymer is preferably biodegradable and exhibits minimal toxicity when administered to animals, including humans.
Selection of Polyphosphazene Polyelectrolytes.
Polyphosphazenes are polymers with backbones consisting of alternating phosphorus and nitrogen, separated by alternating single and double bonds. Each phosphorous atom is covalently bonded to two pendant groups ("R"). The repeat unit in polyphosphazenes has the following general formula: ##STR1## wherein n is an integer.
The substituent ("R") can be any of a wide variety of moieties that can vary within the polymer, including but not limited to aliphatic, aryl, aralkyl, alkaryl, carboxylic acid, heteroaromatic, carbohydrates, including glucose, heteroalkyl, halogen, (aliphatic)amino- including alkylamino-, heteroaralkyl, di(aliphatic)amino- including dialkylamino-, arylamino-, diarylamino-, alkylarylamino-, -oxyaryl including but not limited to -oxyphenylCO2 H, -oxyphenylSO3 H, -oxyphenylhydroxyl and -oxyphenylPO3 H; -oxyaliphatic including -oxyalkyl, -oxy(aliphatic)CO2 H, -oxy(aliphatic)SO3 H, -oxy(aliphatic)PO3 H, and -oxy(aliphatic)hydroxyl, including -oxy(alkyl)hydroxyl; -oxyalkaryl, -oxyaralkyl, -thioaryl, -thioaliphatic including -thioalkyl, -thioalkaryl, -thioaralkyl, --NHC(O)O-(aryl or aliphatic), --O--[(CH2)x O]y --CH2)x NH2, --O--[(CH2)x NH(CH2)x SO3 H, and --O--[(CH2)x O]y -(aryl or aliphatic), wherein x is 1-8 and y is an integer of 1 to 20. The groups can be bonded to the phosphorous atom through, for example, an oxygen, sulfur, nitrogen, or carbon atom.
In general, when the polyphosphazene has more than one type of pendant group, the groups will vary randomly throughout the polymer, and the polyphosphazene is thus a random copolymer. Phosphorous can be bound to two like groups, or two different groups. Polyphosphazenes with two or more types of pendant groups can be produced by reacting poly(dichlorophosphazene) with the desired nucleophile or nucleophiles in a desired ratio. The resulting ratio of pendant groups in the polyphosphazene will be determined by a number of factors, including the ratio of starting materials used to produce the polymer, the temperature at which the nucleophilic substitution reaction is carried out, and the solvent system used. While it is very difficult to determine the exact substitution pattern of the groups in the resulting polymer, the ratio of groups in the polymer can be easily determined by one skilled in the art.
In one embodiment, the immunoadjuvant is a biodegradable polyphosphazene of the formula: ##STR2## wherein A and B can vary independently in the polymer, and can be: (i) a group that is susceptible to hydrolysis under the conditions of use, including but not limited to chlorine, amino acid, amino acid ester (bound through the amino group), imidazole, glycerol, or glucosyl; or
(ii) a group that is not susceptible to hydrolysis under the conditions of use, including, but not limited to an aliphatic, aryl, aralkyl, alkaryl, carboxylic acid, heteroaromatic, heteroalkyl, (aliphatic)amino- including alkylamino-, heteroaralkyl, di(aliphatic)amino- including dialkylamino-, arylamino-, diarylamino-, alkylarylamino-, -oxyaryl including but not limited to -oxyphenylCO2 H, -oxyphenylSO3 H, -oxyphenylhydroxyl and -oxyphenylPO3 H; -oxyaliphatic including -oxyalkyl, -oxy(aliphatic)CO2 H, -oxy(aliphatic)SO3 H, -oxy(aliphatic)PO3 H, and -oxy(aliphatic)hydroxyl, including -oxy(alkyl)hydroxyl; -oxyalkaryl, -oxyaralkyl, -thioaryl, -thioaliphatic including -thioalkyl, -thioalkaryl, or thioaralkyl;
wherein the polymer contains at least one percent or more, preferably 10 percent or more, and more preferably 80 to 90 percent or more, but less than 100%, of repeating units that are not susceptible to hydrolysis under the conditions of use, and
wherein n is an integer of 4 or more, and preferably between 10 and 20,000.
It should be understood that certain groups, such as heteroaromatic groups other than imidazole, hydrolyze at an extremely slow rate under neutral aqueous conditions, such as that found in the blood, and therefore are typically considered nonhydrolyzable groups for purposes herein. However, under certain conditions, for example, low pH, as found, for example, in the stomach, the rate of hydrolysis of normally nonhydrolyzable groups (such as heteroaromatics other than imidazole) can increase to the point that the biodegradation properties of the polymer can be affected. One of ordinary skill in the art using well known techniques can easily determine whether pendant groups hydrolyze at a significant rate under the conditions of use. One of ordinary skill in the art can also determine the rate of hydrolysis of the polyphosphazenes of diverse structures as described herein, and will be able to select that polyphosphazene that provides the desired biodegradation profile for the targeted use.
The degree of hydrolytic degradability of the polymer will be a function of the percentage of pendant groups susceptible to hydrolysis and the rate of hydrolysis of the hydrolyzable groups. The hydrolyzable groups are replaced by hydroxyl groups in aqueous environments to provide P--OH bonds that impart hydrolytic instability to the polymer.
In other embodiments, the immunoadjuvant is: (i) a nonbiodegradable polyphosphazene wherein none, or virtually none, of the pendant groups in the polymer are susceptible to hydrolysis under the conditions of use, or (ii) a completely biodegradable polyphosphazene wherein all of the groups are susceptible to hydrolysis under the conditions of use (for example, poly[di(glycinato)phosphazene]).
Phosphazene polyelectrolytes are defined herein as polyphosphazenes that contain ionized or ionizable pendant groups that render the polyphosphazene anionic, cationic or amphophilic. The ionic groups can be in the form of a salt, or, alternatively, an acid or base that is or can be at least partially dissociated. Any pharmaceutically acceptable monovalent cation can be used as counterion of the salt, including but not limited to sodium, potassium, and ammonium. The phosphazene polyelectrolytes can also contain non-ionic side groups. The phosphazene polyelectrolyte can be biodegradable or nonbiodegradable under the conditions of use. The ionized or ionizable pendant groups are preferably not susceptible to hydrolysis under the conditions of use.
A preferred phosphazene polyelectrolyte immunoadjuvant contains pendant groups that include carboxylic acid, sulfonic acid, or hydroxyl moieties. While the acidic groups are usually on nonhydrolyzable pendant groups, they can alternatively, or in combination, also be positioned on hydrolyzable groups. An example of a phosphazene polyelectrolyte having carboxylic acid groups as side chains is shown in the following formula: ##STR3## wherein n is an integer, preferably an integer between 10 and 10,000. This polymer has the chemical name poly[di(carboxylatophenoxy)phosphazene]or, alternatively, poly[bis(carboxylatophenoxy)phosphazene](PCPP).
The phosphazene polyelectrolyte is preferably biodegradable to prevent eventual deposition and accumulation of polymer molecules at distant sites in the body, such as the spleen. The term biodegradable, as used herein, means a polymer that degrades within a period that is acceptable in the desired application, typically less than about five years and most preferably less than about one year, once exposed to a physiological solution of pH 6-8 at a temperature of approximately 25° C. -37° C.
Most preferably the polymer is a poly(organophosphazene) that includes pendant groups that include carboxylic acid moieties that do not hydrolyze under the conditions of use and pendant groups that are susceptible to hydrolysis under the conditions of use. Examples of preferred phosphazene polyelectrolytes with hydrolysis-sensitive groups are poly[di(carboxylatophenoxy)phosphazene-co-di(amino acid)phosphazene-co(carboxylatophenoxy)(amino acid)phosphazene], specifically including poly[di(carboxylatophenoxy)phosphazene-co-di(glycinato)phosphazene-co(carboxylatophenoxy)(glycinato)phosphazene], and poly[di(carboxylatophenoxy)phosphazene-co-di(chloro)phosphazene-co(carboxylatophenoxy)(chloro)phosphazene].
The toxicity of the polyphosphazene can be determined using cell culture experiments well known to those skilled in the art. For example, toxicity of poly[di(carboxylatophenoxy)phosphazene] was determined in cell culture by coating cell culture dishes with the poly[di(carboxylatophenoxy)phosphazene]. Chicken embryo fibroblasts were then seeded onto the coated petri dishes. Three days after seeding the chicken embryo fibroblasts, the cells had become flattened and spindles formed. Under phase contrast microscopy, mitotic figures were observed. These observations provide evidence of the non-toxicity of poly[di(carboxylatophenoxy)phosphazene] to replicating cells.
Crosslinked polyphosphazenes for use as immunoadjuvants can be prepared by combining a phosphazene polyelectrolyte with a metal multivalent cation such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, or cadmium.
Synthesis of Phosphazene Polyelectrolytes
Polyphosphazenes, including phosphazene polyelectrolytes, can be prepared by a macromolecular nucleophilic substitution reaction of poly(dichlorophosphazene) with a wide range of chemical reagents or mixture of reagents in accordance with methods known to those skilled in the art. Preferably, the phosphazene polyelectrolytes are made by reacting the poly(dichlorophosphazene) with an appropriate nucleophile or nucleophiles that displace chlorine. Desired proportions of hydrolyzable to non-hydrolyzable side chains in the polymer can be obtained by adjusting the quantity of the corresponding nucleophiles that are reacted with poly(dichlorophosphazene) and the reaction conditions as necessary. Preferred polyphosphazenes for immunoadjuvant activity have a molecular weight of over 1,000.
For example, poly[(carboxylatophenoxy)(glycinato)phosphazene] (PC-G1PP) is prepared by the nucleophilic substitution reaction of the chlorine atoms of the poly(dichlorophosphazene) with propyl p-hydroxybenzoate and ethyl glycinato hydrochloride (PC-G1PP synthesis). The poly[(aryloxy)(glycinato)phosphazene] ester thus obtained is then hydrolyzed to the corresponding poly(carboxylic acid). Other polyphosphazenes can be prepared as described by Allcock, H. R.; et al., Inorg. Chem. 11, 2584 (1972); Allcock, H. R.; et al., Macromolecules 16, 715 (1983); Allcock, H. R.; et al., Macromolecules 19,1508 (1986); Allcock, H. R.; et al., Biomaterials 19, 500 (1988); Allcock, H. R.; et al. , Macromolecules 21, 1980 (1988); Allcock, H. R.; et al., Inorg. Chem. 21(2), 515-521 (1982); Allcock, H. R.; et al., Macromolecules 22:75-79 (1989); U.S. Pat. Nos. 4,440,921, 4,495,174, 4,880,622 to Allcock, H. R.; et al.,; U.S. Pat. No. 4,946,938 to Magill, et al., U.S. Pat. No. 5,149,543 to Cohen et al., and the publication of Grolleman, et al., J.Controlled Release 3,143 (1986), the teachings of which, and polymers disclosed therein, are incorporated by reference herein.
Selection of an Antigen
The antigen can be derived from a cell, bacteria, or virus particle, or portion thereof. As defined herein, antigen may be a protein, peptide, polysaccharide, glycoprotein, glycolipid, nucleic acid, or combination thereof, which elicits an immunogenic response in an animal, for example, a mammal, bird, or fish. As defined herein, the immunogenic response can be humoral or cell-mediated. In the event the material to which the immunogenic response is to be directed is poorly antigenic, it may be conjugated to a carrier such as albumin or to a hapten, using standard covalent binding techniques, for example, with one of the several commercially available reagent kits.
In one embodiment, the polymer is used to deliver nucleic acid which encodes antigen to a mucosal surface where the nucleic acid is expressed.
Examples of preferred antigens include viral proteins such as influenza proteins, human immunodeficiency virus (HIV) proteins, and hepatitis B proteins, and bacterial proteins and lipopolysaccharides such as gram negative bacterial cell walls and Neisseria gonorrhea proteins.
Preparation of an Immunogenic Composition
Combining Antigen with polymer for simultaneous administration.
An immunogenic composition, or vaccine, is prepared by combining the polymer adjuvant with an antigen. Approximately 0.5-0.0001 parts of antigen is added to one part polymer, preferably by stirring a solution of polymer and antigen until a solution or suspension is obtained, preferably for 10 minutes or more at 25° C. The polymer is preferably combined with the antigen using a method dispersing the antigen uniformly throughout the adjuvant. Methods for liquifying the polymer include dissolving the polymer in an aqueous-based solvent, preferably having a pH range of between 7.1 and 7.7, and melting the polymer. The latter is useful only when the antigen is stable at the polymer melting temperature. The antigen is then mixed with the polymer. The polymer and the antigen, in solid form, for example, when the antigen is lyophilized, can also be physically mixed together, for example, by compression molding. The polymer can also be used to encapsulate the antigen, for example, using the method of U.S. Pat. No. 5,149,543 to Cohen, et al., the teachings of which are incorporated herein, or by spray drying a solution of polymer and antigen. Alternatively, microspheres containing the antigen and adjuvant can be prepared by simply mixing the components in an aqueous solution, and then coagulating the polymer together with the substance by mechanical forces to form a microparticle. The microparticle can be stabilized, if necessary or desired, using electrolytes, pH changes, organic solvents, heat or frost to form polymer matrices encapsulating biological material.
In a preferred embodiment, approximately one part of polymer is dissolved in 10 parts 3% Na2 CO3 aqueous solution while stirring, then 10 to 90 parts phosphate buffer pH 7.4 is slowly added.
Polymer-Antigen Conjuates
The polymer can also be covalently conjugated with the antigen to create a water-soluble conjugate in accordance with methods well-known to those skilled in the art, usually by covalent linkage between an amino or carboxyl group on the antigen and one of the ionizable side groups on the polymer.
Cross-linked Polymer Adjuvant
In an alternative preferred embodiment, the polymer is cross-linked with a multivalent ion, preferably using an aqueous solution containing multivalent ions of the opposite charge to those of the charged side groups of the polyphosphazene, such as multivalent cations if the polymer has acidic side groups or multivalent anions if the polymer has basic side groups.
Preferably, the polymers are cross-linked by di and trivalent metal ions such as calcium, copper, aluminum, magnesium, strontium, barium, tin, zinc, and iron, organic cations such as poly(amino acid)s, or other polymers such as poly(ethyleneimine), poly(vinylamine) and polysaccharides.
Additives to the polymer-adjuvant mixture.
It will be understood by those skilled in the art that the immunogenic vaccine composition can contain other physiologically acceptable ingredients such as water, saline or a mineral oil such as Drakeol™, Markol™, and squalene to form an emulsion
Administration of Polymer-Antigen Vaccine
The immunogenic composition can be administered as a vaccine by any method known to those skilled in the art that elicits an immune response, including parenterally, orally, or by transmembrane or transmucosal administration. Preferably, the vaccine is administered parenterally (intravenously, intramuscularly, subcutaneously, intraperitoneally, etc.), and preferably subcutaneously. Nonlimiting examples of routes of delivery to mucosal surfaces are intranasal (or generally, the nasal associated lymphoid tissue), respiratory, vaginal, and rectal.
The dosage is determined by the antigen loading and by standard techniques for determining dosage and schedules for administration for each antigen, based on titer of antibody elicited by the polymer-antigen administration, as demonstrated by the following examples.
Although in the preferred embodiment the polymer-antigen mixture is administered simultaneously, in an alternative embodiment, the polymer and antigen are administered separately to the same or nearby site. The polymer serves to attract cells of the immune system to the site, where they process the antigen.
The polyphosphazene adjuvants and methods of synthesis will be further understood by reference to the following non-limiting examples.
EXAMPLE 1 Synthesis of poly[(carboxylatophenoxy)(glycinato)phosphazene].
Poly[(carboxylatophenoxy)(glycinato)phosphazene]was prepared as follows. Poly(dichlorophosphazene) (5.0, 0.0425 moles) was dissolved in 300 ml tetrahydrofuran (THF). The sodium salt of propyl p-hydroxybenzoate (prepared by reacting propyl hydroxybenzoate (30.6 g, 0.17 moles) with 60% sodium hydride (6.12, 0.15 moles) in THF) was added dropwise to the dissolved polymer. After addition of the sodium salt, the reaction mixture was stirred at reflux for 2 days and monitored by 31 P NMR.
Ethyl glycinate hydrochloride (23.63 g, 0.17 moles) was suspended in 50 ml toluene containing triethylamine (23.69, 0.17 moles) and refluxed for 3.5 hours. The reaction mixture was cooled in an ice bath and triethylamine hydrochloride precipitated from the solution. The solution was filtered and added to the polymer mixture at 0° C. The reaction mixture was allowed to warm to room temperature and stirred for 2 days. The polymer was purified by repeated precipitations into 100% ethanol.
The resulting polymer (0.5 g, 1.33 mmol) was dissolved in dry THF (20 ml). The solution was added slowly to a mixture of potassium tert-butoxide and water in dry THF. For the first 5 minutes, the mixture was cooled to 0° C.; it was then stirred at room temperature for 40 hours. A large excess of ice water (300 ml) was added, and the solution was concentrated by evaporation. The polymer was isolated by acidification of the solution with hydrochloric acid to pH 5.5. The conditions of reactions and weight average molecular weights of obtained polymers measured by gel permeation chromatography in water is shown in Table 1 below.
              TABLE 1                                                     
______________________________________                                    
Synthesis of poly[(carboxylatophenoxy)                                    
(glycinato)phosphazene].                                                  
    Concen-    Concen-                                                    
    tration    tration    Concen-                                         
    of polymer of potassium                                               
                          tration Reaction                                
    % w/v      tert-      of water                                        
                                  time   MW                               
No  mol/l      butoxide   mol/l   hours  kDa                              
______________________________________                                    
1   0.42       0.30       0.1     42     80                               
2   0.42       0.15       0.05    18     130                              
3   0.42       0.04       0.05    5      170                              
______________________________________                                    
 The structures of polymers were confirmed by .sup.1 H and .sup.31 P NMR  
 (JEOL FX90Q NMR spectrometer) and elemental microanalysis.               
EXAMPLE 2 Synthesis of Poly[di(carboxylatophenoxy)phosphazene].
Poly[di(carboxylatophenoxy)phosphazene] was prepared by chemical modification of poly(dichlorophosphazene) with the sodium salt of propyl p-hydroxybenzoate, followed by hydrolysis of ester groups to carboxylic acid as described in Allcock, H. R. & Kwon, S. (1989) Macromolecules 22, 75-79, the teachings of which are incorporated herein.
EXAMPLE 3 Synthesis of poly[(carboxylatophenoxy)(chloro)phosphazene].
Poly[(carboxylatophenoxy)(chloro)phosphazene] was prepared as follows. Poly[di(chloro)phosphazene] (5.0 g, 0.0425 moles) was dissolved in 300 mL tetrahydrofuran (THF). The sodium salt of propyl p-hydroxybenzoate, prepared by reacting propyl hydroxybenzoate (30.6 g, 0.17 moles) with 60 % sodium hydride (6.12 g, 015 moles) in THF, was added dropwise to the dissolved polymer. After addition of the sodium salt, the reaction mixture was stirred at reflux for 2 days and monitored by 31 P NMR. The polymer was purified by repeated precipitations into water, ethanol and hexane.
Poly[(propylhydroxybenzoate)(chloro)phosphazene] (2.0 g) was dissolved in 200 mL dry THF. 20 g potassium tert-butoxide was dissolved in 200 mL THF. The basic solution was cooled to 0° C. Water (1 mL) was added to the butoxide/THF solution and stirred for 5 minutes. The polymer solution then was added dropwise to the aqueous base. The reaction mixture was warmed to room temperature and stirred for 40 hours. After 40 hours, the reaction mixture was poured over an ice-water mixture and the THF was allowed to evaporate. The aqueous solution was then dialyzed against water for 2 days. After dialysis was complete, the dialysate was acidified with HCl and the resultant white precipitate, poly[(carboxylatophenoxy)(chloro)phosphazene], was washed with water and filtered from the solution.
EXAMPLE 4 Degradation of Phosphazene Polyelectrolytes
Degradation of phosphazene polyelectrolytes was studied in vitro at 37° C., in an air gravity incubator (Imperial II Incubator, Lab-Line Instruments, Inc.), with gentle agitation on a rotating shaker (ORBIT Shaker, Lab-Line Instruments, Inc., Melrose Park, Ill.) in vials containing a solution of 50 mg of polymer in 5 ml of 13 mM HEPES buffered saline solution (pH 7.4). The molecular weight of polyphosphazenes was determined by a Perkin-Elmer Series 10 liquid chromatograph with refractive index and a refractive index detector by using an Ultragel 2000 column (Waters Chromatography Division, Millipore Corporation, Cidra, Puerto Rico). 13 mM Hepes buffered saline solution (pH 7.4) was used as an eluant. Chromatograms were processed by GPC 5 and CHROM 2 software (Perkin-Elmer) to calculate the weight-average and number-average molecular weights using polyacrylic acid as a standard. The decline in polymer molecular weight over time is shown in Table 2.
              TABLE 2                                                     
______________________________________                                    
Degradation of Poly[(carboxylatophenoxy)                                  
(glycinato)phosphazene].                                                  
          Weight average                                                  
                       Number average                                     
Time      molecular weight                                                
                       molecular weight                                   
days      kDa          kDa                                                
______________________________________                                    
0         132.0        70.0                                               
15        40.6         13.8                                               
60        6.3          1.5                                                
180       6.0          0.9                                                
240       0.9          0.5                                                
______________________________________                                    
EXAMPLE 5 Antibody Titers after Immunization with Tetanus Toxoid in Various Concentrations of a Polyphosphazene Adjuvant.
Antibody titers were determined in female BALB/c mice, age 7 to 8 weeks, that had been inoculated with tetanus toxoid admixed with a polyphosphazene adjuvant.
An immunogenic composition containing tetanus toxoid in polyphosphazene was prepared as follows. 100 mg of poly[di(carboxylatophenoxy)phosphazene] was dissolved in 1 ml Na2 CO3 and 1 ml phosphate buffered saline (PBS), pH 7.2 was added. 1.4 ml tetanus toxoid (2.2 mg/ml or 1000 LF/ml, Connaught Laboratories, Inc., Swiftwater, Pa.) was added with 0.6 ml containing 0.025% Brij solution (10 μl of 10% Brij 58, Sigma Chemical Co., St. Louis, Mo.) to the polymer.
Groups of five mice were immunized subcutaneously with a single dose of 25 μg tetanus toxoid admixed with dilutions containing 0.5% polyphosphazene, 0.05% polyphosphazene, or 0.005% polyphosphazene in dH20. A separate group of mice was immunized with a single subcutaneous dose of 25 μg of tetanus toxoid in complete Freund's adjuvant (SIGMA, St. Louis, Mo.). Blood samples were taken from the retroorbital sinus of CO2 anaesthetized mice and analyzed by an ELISA immunoassay for anti-tetanus toxoid IgG.
As shown in Table 3 below, 25 μg of tetanus toxoid in 0.5% polyphosphazene gave anti-tetanus specific serum IgG titers slightly higher than the same dose in complete Freund's adjuvant. 25 μg of tetanus toxoid in 0.05% polyphosphazene gave titers that were slightly lower than the same dose in complete Freund's adjuvant. In all cases, the titer of antibody against tetanus toxoid was significantly higher when administered in conjunction with polymer than when administered alone.
              TABLE 3                                                     
______________________________________                                    
Anti-tetanus titers in mice after administration of tetanus               
toxoid with a polyphosphazene adjuvant or Freund's adjuvant.              
           Anti-tetanus toxoid ELISA titer (log 2)                        
Group Treatment                                                           
             Week 3    Week 5     Week 7                                  
______________________________________                                    
25 μg TT/0.5% PP                                                       
             65536 (16)                                                   
                       262144 (18)                                        
                                  524288 (19)                             
25 μg TT/0.05% PP                                                      
             16384 (14)                                                   
                        32768 (15)                                        
                                   32768 (15)                             
25 μg TT/0.005% PP                                                     
              4096 (12)                                                   
                        8192 (13)  32768 (15)                             
25 μg TT in Freund's                                                   
             16384 (14)                                                   
                       131072 (17)                                        
                                  262144 (18)                             
25 μg TT in H.sub.2 O                                                  
              1024 (10)                                                   
                        2048 (11)  2048 (11)                              
______________________________________                                    
 The letters "TT" are an abbreviation for tetanus toxoid whereas "PP" is a
 abbreviation for polyphosphazene.                                        
EXAMPLE 6 Antibody Titers after Immunization with Various Concentrations of Tetanus Toxoid or Influenza Admixed with a Polyphosphazene Adjuvant.
Antibody titers were determined in female BALB/c mice, age 7 to 8 weeks, that had been inoculated with either influenza or tetanus toxoid admixed with the polyphosphazene adjuvant described in Example 5.
Two immunogenic compositions, one containing tetanus toxoid in polyphosphazene and the other containing influenza in polyphosphazene, were prepared as follows. 100 mg of poly[di(carboxylatophenoxy) phosphazene] was dissolved in 1 ml Na2 CO3 and 1 ml phosphate buffered saline (PBS), pH 7.6 was added. Subsequently, tetanus toxoid (2.2 mg/ml) (Connaught Laboratories, Swiftwater, Pa.) or influenza (Influenza Branch, Center for Disease Control, Atlanta, Ga.) was diluted 1:10 in water and the appropriate volume of each was admixed with either 0.1% or 0.05% polyphosphazene.
Groups of three mice were immunized subcutaneously with a single dose of each immunogenic composition. Blood samples were taken from the retroorbital sinus of CO2 anaesthetized mice after 21 days after inoculation and analyzed by an ELISA immunoassay for anti-tetanus toxoid or anti-influenza IgG.
The following influenza immunoassay protocol was performed to determine the influenza titers: 96-well ELISA microtiter plates were coated with influenza cell lysates at 10 μg/ml in carbonate buffer, pH 9.6, 100 ml per well and incubated 2 hours at 37° C. The plate was washed with 0.05% Tween 20/PBS (Sigma, St. Louis, Mo.) and 100 μl 12.5% bovine serum albumin/phosphate buffered saline (BSA/PBS) was added to each well as a blocking step. The plate was then incubated 1 hour at 37° C. and washed with 0.05% Tween 20/PBS. 50 μl 1% BSA/PBS was added to all wells. Serum samples were diluted to 1:128 by adding 5 μl serum to 635 μl % BSA/PBS. 50 μl of the dilute serum sample to be assayed was added to the first well in a row, a 1:256 dilution. Both positive and negative controls were tested. Two-fold serial dilutions of serum sample were made by removing 50 μl from the first well in a row and adding the 50 μl with mixing to the second well; then removing 50 μl from the second well and adding it to the third well with mixing, and so on down the row, discarding 50 μl from the final or 12th well. The plates were then incubated 1 hour at 37° C. and the plate washed with 0.05% Tween 20/PBS. To each well was added 100 μl of OPD solution (0.4 mg/ml solution of 0-phenylenediamine dihydrochloride (Sigma, St. Louis, Mo.) in 0.05 M phosphate-citrate buffer pH 5.0 (1 OPD tablet per 12.5 ml citrate buffer) containing 0.05% hydrogen peroxide (20.8 μl 30% H2 O2 per 12.5 ml citrate buffer)). The color was allowed to develop for 30 minutes, then stopped by addition of 50 μl 2M H2 SO4 / well. The absorbance was read at OD490, and the endpoint titer determined by finding the dilution of each serum sample that had an OD490 greater than or equal to two times the OD490 of the negative control at the same dilution.
As shown below in Tables 4 and 5, 25 mg of tetanus toxoid (TT) and 5 μg of influenza (flu), in combination with 0.1% polyphosphazene (PP), yielded serum IgG titers that were the same or higher than the same dose of antigen administered in complete Freund's adjuvant.
              TABLE 4                                                     
______________________________________                                    
Antibody Titers After Administration of                                   
Tetanus Toxoid Admixed with a Polyphosphazene                             
Adjuvant or Freund's adjuvant.                                            
Treatment      Anti-Tetanus Toxoid Titer (log2)                           
______________________________________                                    
 25 μg TT/0.1% PP                                                      
               16384 (14)                                                 
  5 μg TT/0.1% PP                                                      
               4096 (12)                                                  
  1 μg TT/0.1% PP                                                      
               2048 (11)                                                  
0.2 μg TT/0.1% PP                                                      
               512 (9)                                                    
 25 μg TT/0.05% PP                                                     
               8192 (13)                                                  
  5 μg TT/0.05% PP                                                     
               4096 (12)                                                  
  1 μg TT/0.05% PP                                                     
               2048 (11)                                                  
0.2 μg TT/0.05% PP                                                     
               512 (9)                                                    
 25 μg TT in water                                                     
               2048 (11)                                                  
 25 μg TT in Freund's                                                  
               16384 (14)                                                 
______________________________________                                    
              TABLE 5                                                     
______________________________________                                    
Antibody Titers After Administration of                                   
Influenza Admixed with a Polyphosphazene                                  
Adjuvant or Freund's adjuvant.                                            
Treatment      Anti-Influenza Titer (log2)                                
______________________________________                                    
  5 μg flu/0.1% PP                                                     
               2048 (11)                                                  
  1 μg flu/0.1% PP                                                     
               4096 (12)                                                  
 0.2 μg flu/0.1% PP                                                    
               <256 (<8)                                                  
0.04 μg flu/0.1% PP                                                    
               <256 (<8)                                                  
  5 μg flu/0.05% PP                                                    
               4096 (12)                                                  
  1 μg flu/0.05% PP                                                    
               1024 (10)                                                  
 0.2 μg flu/0.05% PP                                                   
               <256 (<8)                                                  
0.04 μg flu/0.05% PP                                                   
               <256 (<8)                                                  
  5 μg flu in water                                                    
               256 (8)                                                    
  5 μg flu in Freund's                                                 
               512 (9)                                                    
______________________________________                                    
EXAMPLE 7 Influenza Hemagglutination Inhibition Titers after Immunization with Influenza Admixed with a Polyphosphazene Adjuvant.
An influenza hemagglutination inhibition antibody assay was performed with heat-inactivated mouse serum that had been incubated for 30 minutes with 10% chicken red blood cells (Spafas, Storrs, Conn.) to remove nonspecific inhibitors. Two-fold dilutions of sera were added to a 96-well microtiter plate and 8 hemagglutination (HA) units of virus suspension in a equal volume were added to each well and incubated at room temperature for 30 minutes. A 0.5% suspension of chicken red blood cells was added to each well and incubated at room temperature for 45-60 minutes.
Hemagglutination inhibition (HI) titers are expressed in Table 6 below as the reciprocal of the highest dilution that completely inhibits hemagglutination of erythrocytes.
As shown in Table 6, hemagglutination titers of animals inoculated with flu in combination with 0.1% polyphosphazene were high, while titers for flu in combination with complete Freund's adjuvant were negative.
              TABLE 6                                                     
______________________________________                                    
Hemagglutination Inhibition Titers After                                  
Administration of Influenza Admixed with a                                
Polyphosphazene Adjuvant or Freund's adjuvant.                            
Treatment                                                                 
Inhibition Titers                                                         
                 Hemagglutination                                         
______________________________________                                    
  5 μg flu/0.1% PP                                                     
                 160                                                      
  1 μg flu/0.1% PP                                                     
                 320                                                      
 0.2 μg flu/0.1% PP                                                    
                  40                                                      
0.04 μg flu/0.1% PP                                                    
                 negative                                                 
  5 μg flu/0.05% PP                                                    
                 160                                                      
  1 μg flu/0.05% PP                                                    
                 160                                                      
 0.2 μg flu/0.05% PP                                                   
                 negative                                                 
0.04 μg flu/0.05% PP                                                   
                 negative                                                 
  5 μg flu in water                                                    
                 negative                                                 
  5 μg flu in Freund's                                                 
                 negative                                                 
______________________________________                                    
EXAMPLE 8 Antibody Titers after Immunization with Tetanus Toxoid or Influenza Admixed with Various Concentrations of Two Different Polyphosphazene Polymer Adjuvants.
100 mg of poly[di(carboxylatophenoxy) phosphazene] (Polymer 1) was dissolved in 1 ml Na2 CO3 and 3 ml of PBS was added to the polymer solution. 100 mg of poly[(carboxylatophenoxy)(glycinato)phosphazene] (Polymer 2) was dissolved in the same solvents.
Antibody titers were determined in groups of female BALB/c mice, three mice per group, age 7 to 8 weeks, 21 days after inoculation with 5 μg influenza admixed with one of each of the polymers.
As shown below in Table 7, 5 μg of flu in 0.1% or 0.05% of polymer 1 or polymer 2 give serum IgG titers that are higher than the same dosage of antigen in complete Freund's adjuvant.
              TABLE 7                                                     
______________________________________                                    
Antibody Titers After Administration of                                   
Influenza Admixed with                                                    
Poly[di(carboxylatophenoxy)phosphazene]                                   
(Polymer 1), Poly[(carboxylatophenoxy)-                                   
(glycinato)phosphazene] (Polymer 2) or                                    
Freund's adjuvant.                                                        
Treatment        Anti-Influenza Titer (log2)                              
______________________________________                                    
5 μg flu in water                                                      
                 <256 (<8)                                                
5 μg flu in Freund's                                                   
                 256 (8)                                                  
5 μg flu/0.1% Polymer 2                                                
                 1024 (10)                                                
5 μg flu/0.05% Polymer 2                                               
                 512 (9)                                                  
5 μg flu/0.01% Polymer 1                                               
                 4096 (12)                                                
5 μg flu/0.05% Polymer 1                                               
                 4096 (12)                                                
______________________________________                                    
Modifications and variations of the present invention, polymer adjuvants and methods of synthesis and use in vaccine compositions, will be obvious to those skilled in the art from the foregoing detailed description. Such modifications and variations are intended to come within the scope of the appended claims.

Claims (6)

We claim:
1. A composition comprising:
a synthetic water-soluble phosphazene polyelectrolyte consisting of a poly[di(carboxylatophenoxy)phosphazene-co-di(amino acid)phosphazene-co-(carboxylatophenoxy)(amino acid)phosphazene].
2. The composition of claim 1 wherein the phosphazene polyelectrolyte is cross-linked with a multivalent cation.
3. The composition of claim 2 wherein the multivalent cation is selected from the group consisting of calcium, copper, aluminum, magnesium, strontium, barium, tin, zinc, iron, poly(amino acid), poly(ethyleneimine), poly(vinylamine) and polysaccharides.
4. The composition of claim 1 wherein the phosphazene polyelectrolyte is biodegradable.
5. Poly[di(carboxylatophenoxy)phosphazene-co-di(glycinato)phosphazene-co-(carboxylatophenoxy)(glycinato)phosphazene].
6. Poly[di(carboxylatophenoxy)phosphazene-co-di(chloro)phosphazene-co-(carboxylatophenoxy)(chloro)phosphazene].
US08/090,841 1993-07-12 1993-07-12 Phosphazene polyelectrolytes as immunoadjuvants Expired - Fee Related US5562909A (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
US08/090,841 US5562909A (en) 1993-07-12 1993-07-12 Phosphazene polyelectrolytes as immunoadjuvants
US08/147,781 US5529777A (en) 1993-07-12 1993-11-04 Hydrogel microencapsulated vaccines
AT94923378T ATE207505T1 (en) 1993-07-12 1994-07-08 PHOSPHAZENES AND POLYELECTROLYTES AS IMMUNE ADJUVANTS
PCT/US1994/007665 WO1995002415A1 (en) 1993-07-12 1994-07-08 Phosphazene polyelectrolytes as immunoadjuvants
CA2166208A CA2166208C (en) 1993-07-12 1994-07-08 Phosphazene polyelectrolytes as immunoadjuvants
AU73261/94A AU691824B2 (en) 1993-07-12 1994-07-08 Phosphazene polyelectrolytes as immunoadjuvants
JP7504624A JPH09500629A (en) 1993-07-12 1994-07-08 Phosphazene polyelectrolytes as immunoadjuvants
PT94923378T PT710117E (en) 1993-07-12 1994-07-08 POLYETHECTROLITES BASED ON PHOSPHAZEN AS IMMUNOADHANTS
DK94923378T DK0710117T3 (en) 1993-07-12 1994-07-08 Phosphazene polyelectrolytes as immunoadjuvants
KR1019960700227A KR100352336B1 (en) 1993-07-12 1994-07-08 Phosphagen Polymer Electrolytes As Adjuvant
DE69428795T DE69428795T2 (en) 1993-07-12 1994-07-08 PHOSPHAZENE AND POLYELECTROLYTE AS IMMUNA ADJUVANTS
BR9407051A BR9407051A (en) 1993-07-12 1994-07-08 Phosphazene polyelectrolytes as immunoadjuvants
ES94923378T ES2166376T3 (en) 1993-07-12 1994-07-08 PHOSPHACENE POLYELECTROLYTES AS IMMUNOADJUVANTS.
NZ269396A NZ269396A (en) 1993-07-12 1994-07-08 Vaccine comprising an antigen and a water soluble polyphosphazene polyelectrolyte
SG1996007424A SG46659A1 (en) 1993-07-12 1994-07-08 Phosphazene polyelectrolytes as immunoadjuvants
CNB94193067XA CN1134265C (en) 1993-07-12 1994-07-08 Phosphazene polyelectrolytes as immunoadjuvants
EP94923378A EP0710117B1 (en) 1993-07-12 1994-07-08 Phosphazene polyelectrolytes as immunoadjuvants
NZ269411A NZ269411A (en) 1993-07-12 1994-07-11 Hydrogel microencapsulated vaccines containing antigens
CN94193066A CN1128953A (en) 1993-07-12 1994-07-11 Hydrogel microencapsulated vaccines
PCT/US1994/007749 WO1995002416A1 (en) 1993-07-12 1994-07-11 Hydrogel microencapsulated vaccines
AU73286/94A AU690567B2 (en) 1993-07-12 1994-07-11 Hydrogel microencapsulated vaccines
US08/273,285 US5494673A (en) 1993-07-12 1994-07-11 Phosphazene polyelectrolytes as immunoadjuvants
BR9407397A BR9407397A (en) 1993-07-12 1994-07-11 Hydrogel microencapsulated vaccines
EP94923417A EP0792161A4 (en) 1993-07-12 1994-07-11 Hydrogel microencapsulated vaccines
CA002167081A CA2167081A1 (en) 1993-07-12 1994-07-11 Hydrogel microencapsulated vaccines
JP7504650A JPH09500132A (en) 1993-07-12 1994-07-11 Hydrogel microencapsulated vaccine
KR1019960700228A KR100353496B1 (en) 1993-07-12 1994-07-11 Hydrogel Microencapsulated Vaccine
PCT/US1994/007710 WO1995002628A1 (en) 1993-07-12 1994-07-12 Polyphosphazenes useful as immunoadjuvants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/090,841 US5562909A (en) 1993-07-12 1993-07-12 Phosphazene polyelectrolytes as immunoadjuvants

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08/147,781 Continuation-In-Part US5529777A (en) 1993-07-12 1993-11-04 Hydrogel microencapsulated vaccines
US08/273,285 Continuation-In-Part US5494673A (en) 1993-07-12 1994-07-11 Phosphazene polyelectrolytes as immunoadjuvants

Publications (1)

Publication Number Publication Date
US5562909A true US5562909A (en) 1996-10-08

Family

ID=22224581

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/090,841 Expired - Fee Related US5562909A (en) 1993-07-12 1993-07-12 Phosphazene polyelectrolytes as immunoadjuvants
US08/147,781 Expired - Lifetime US5529777A (en) 1993-07-12 1993-11-04 Hydrogel microencapsulated vaccines
US08/273,285 Expired - Lifetime US5494673A (en) 1993-07-12 1994-07-11 Phosphazene polyelectrolytes as immunoadjuvants

Family Applications After (2)

Application Number Title Priority Date Filing Date
US08/147,781 Expired - Lifetime US5529777A (en) 1993-07-12 1993-11-04 Hydrogel microencapsulated vaccines
US08/273,285 Expired - Lifetime US5494673A (en) 1993-07-12 1994-07-11 Phosphazene polyelectrolytes as immunoadjuvants

Country Status (16)

Country Link
US (3) US5562909A (en)
EP (1) EP0710117B1 (en)
JP (1) JPH09500629A (en)
KR (2) KR100352336B1 (en)
CN (1) CN1134265C (en)
AT (1) ATE207505T1 (en)
AU (1) AU691824B2 (en)
BR (1) BR9407051A (en)
CA (1) CA2166208C (en)
DE (1) DE69428795T2 (en)
DK (1) DK0710117T3 (en)
ES (1) ES2166376T3 (en)
NZ (1) NZ269396A (en)
PT (1) PT710117E (en)
SG (1) SG46659A1 (en)
WO (2) WO1995002415A1 (en)

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898062A (en) * 1996-04-10 1999-04-27 The Penn State Research Foundation Poly (organophosphazene) hydrogels
WO2000025815A1 (en) * 1998-10-30 2000-05-11 Avant Immunotherapeutics, Inc. Novel immunoadjuvants
US6077916A (en) * 1997-06-04 2000-06-20 The Penn State Research Foundation Biodegradable mixtures of polyphoshazene and other polymers
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
US6207171B1 (en) * 1998-03-27 2001-03-27 Avant Immunotherapeutics, Inc. Polyphosphazene microspheres
US20030092665A1 (en) * 1997-04-30 2003-05-15 Compans Richard W. Methods and compositions for administering DNA to mucosal surfaces
WO2003046054A2 (en) * 2001-11-29 2003-06-05 Parallel Solutions, Inc. Copolymer libraries and production and use thereof
US6605237B2 (en) * 2000-06-29 2003-08-12 The Penn State Research Foundation Polyphosphazenes as gel polymer electrolytes
US20030165478A1 (en) * 2002-02-14 2003-09-04 Sokoll Kenneth K. Stabilized synthetic immunogen delivery system
US20040077528A1 (en) * 1999-06-29 2004-04-22 Mannkind Corporation Purification and stabilization of peptide and protein pharmaceutical agents
US20040096403A1 (en) * 1995-05-15 2004-05-20 Mannkind Corporation Method for drug delivery to the pulmonary system
US20050088617A1 (en) * 2003-10-27 2005-04-28 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics
US20060016331A1 (en) * 2004-05-13 2006-01-26 Stewart Frederick F Phosphazene membranes for gas separations
US20060088476A1 (en) * 2004-10-25 2006-04-27 Polyzenix Gmbh Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US20070020191A1 (en) * 1999-06-29 2007-01-25 Mannkind Corporation Potentiation of glucose elimination
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20090004526A1 (en) * 2005-03-29 2009-01-01 Toyota Motor Engineering & Manufacturing North America, Inc. Proton exchange membrane for fuel cell
US20090016935A1 (en) * 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
WO2010043039A1 (en) 2008-10-16 2010-04-22 University Of Saskatchewan Combination adjuvant formulation
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7718609B2 (en) 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2013116639A1 (en) 2012-02-01 2013-08-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Campylobacter immunogenic compositions and uses thereof
US8933023B2 (en) 2004-03-12 2015-01-13 Biodel Inc. Rapid acting injectable insulin compositions
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US9080146B2 (en) 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
US9107850B2 (en) 2004-10-25 2015-08-18 Celonova Biosciences, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US9114162B2 (en) 2004-10-25 2015-08-25 Celonova Biosciences, Inc. Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9252455B1 (en) * 2010-04-14 2016-02-02 Hrl Laboratories, Llc Lithium battery structures employing composite layers, and fabrication methods to produce composite layers
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9346766B2 (en) 2004-08-20 2016-05-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10342938B2 (en) 2008-06-13 2019-07-09 Mannkind Corporation Dry powder drug delivery system
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10625034B2 (en) 2011-04-01 2020-04-21 Mannkind Corporation Blister package for pharmaceutical cartridges
US10973770B2 (en) 2004-10-25 2021-04-13 Varian Medical Systems, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US11397282B1 (en) 2018-06-29 2022-07-26 Hrl Laboratories, Llc Infrared-transparent polymer optics and methods of making and using the same
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US11779629B2 (en) * 2016-11-09 2023-10-10 The University Of British Columbia Compositions comprising cyclic peptides derived from an A-beta peptide
US11905318B2 (en) 2015-11-09 2024-02-20 The University Of British Columbia Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
AU738698B2 (en) * 1994-07-08 2001-09-27 Avant Immunotherapeutics, Inc. Polyphosphazene polyelectrolyte immunoadjuvants
US5855895A (en) * 1995-06-07 1999-01-05 Virus Research Institute Polyphosphazene polyelectrolyte immunoadjuvants
FR2732605B1 (en) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc COMPOSITION FOR INDUCING MUCOSAL IMMUNE RESPONSE
US5891444A (en) * 1995-06-07 1999-04-06 Virus Research Institute, Inc. HIV-1 prophylactic composition and method
US5900238A (en) * 1995-07-27 1999-05-04 Immunex Corporation Vaccine delivery system
EP0787201B1 (en) * 1995-08-17 2004-04-28 Crucell Holland B.V. Poly(organo)phosphazenes for use in synthetic transfection systems
ATE192334T1 (en) * 1995-11-09 2000-05-15 Microbiological Res Authority MICRO-ENCAPSULED DNA FOR VACCINATION AND GENE THERAPY
US6126964A (en) * 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US5807757A (en) * 1996-07-02 1998-09-15 Virus Research Institute, Inc. Preparation of ionically cross-linked polyphosphazene microspheresy by coacervation
US6303300B1 (en) * 1996-08-16 2001-10-16 Introgen B.V. Poly (organo) phosphazenes for use in synthetic transfection systems
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
US5760271A (en) * 1997-08-18 1998-06-02 Virus Research Institute, Inc. Production of polyorganophosphazenes
DK1009386T3 (en) * 1997-08-29 2005-09-19 Corixa Corp Fast-releasing encapsulated bioactive agents to induce or potentiate an immune response and methods for its use.
US5958414A (en) * 1997-09-03 1999-09-28 Heska Corporation Composition to protect a mammal against Bartonella henselae infection
WO1999018934A1 (en) * 1997-10-09 1999-04-22 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
US6726934B1 (en) 1997-10-09 2004-04-27 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
SE9801288D0 (en) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and method of production
US6506385B1 (en) 1998-04-17 2003-01-14 Embrex, Inc. Live vaccines and methods of treatment therewith
AU3895499A (en) * 1998-05-11 1999-11-29 Purdue Research Foundation Methods and compositions for nucleic acid delivery
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US7087236B1 (en) * 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US6696089B2 (en) 1998-09-03 2004-02-24 Board Of Regents Of The University Of Nebraska Nanogel networks including polyion polymer fragments and biological agent compositions thereof
US6333051B1 (en) * 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
US5952232A (en) * 1998-09-17 1999-09-14 Rothman; James Edward Expandible microparticle intracellular delivery system
EP1140164B1 (en) * 1998-12-17 2009-02-11 Sanofi Pasteur Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
US6333194B1 (en) 1999-01-19 2001-12-25 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US6258864B1 (en) 1999-01-20 2001-07-10 Cabot Corporation Polymer foam containing chemically modified carbonaceous filler
US6586501B1 (en) 1999-01-20 2003-07-01 Cabot Corporation Aggregates having attached polymer groups and polymer foams
AT407958B (en) * 1999-02-11 2001-07-25 Immuno Ag INACTIVATED INFLUENZA VIRUS VACCINE FOR NASAL OR ORAL APPLICATION
US6521431B1 (en) 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
WO2001001964A2 (en) 1999-06-23 2001-01-11 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
US20020009466A1 (en) * 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
AU7085400A (en) * 1999-09-02 2001-03-26 Antigenics, Inc. Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
DE60038971D1 (en) 1999-10-22 2008-07-03 Aventis Pasteur PROCESS FOR EXPLORING AND / OR REINFORCING THE IMMUNE RESPONSE AGAINST TUMORANTIGENE
GB0000001D0 (en) * 2000-01-05 2000-02-23 Du Pont Uk Pharmaceutical compositions and their preparation
AU2001263760A1 (en) 2000-04-11 2001-11-07 Polyzenix Gmbh Poly-tri-fluoro-ethoxypolyphosphazene coverings and films
EP1792995A3 (en) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
ATE513913T1 (en) 2000-05-10 2011-07-15 Sanofi Pasteur Ltd IMMUNOGENIC POLYPEPTIDES ENCODED BY MAGE MINIGENE AND USES THEREOF
US6740409B1 (en) * 2000-11-15 2004-05-25 Board Of Trustees Of University Of Illinois Polymer films
DE10100961B4 (en) 2001-01-11 2005-08-04 Polyzenix Gmbh Body-compatible material and substrate coated with this material for the cultivation of cells and artificial organic implants constructed or grown from cells
ES2178961B1 (en) * 2001-03-06 2004-07-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. MANUFACTURE OF NANOPARTICULES BASED ON THE COPYLIMER OF METHYL VINYL ETER AND MALEIC ANHYDRIDE FOR THE ADMINISTRATION OF PHARMACES OF HYDROPHYLICAL NATURE, IN PARTICULAR OF PURIC BASES AND PYRIMIDINICS.
CA2452382A1 (en) * 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
ATE340551T1 (en) 2001-08-17 2006-10-15 Polyzenix Gmbh DEVICE BASED ON NITINOL WITH POLYPHOSPHAZENE COVER
CA2479920A1 (en) * 2002-03-29 2003-10-09 The Regents Of The University Of California Microgel particles for the delivery of bioactive materials
DE10224352A1 (en) * 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive polymer carrier with changeable physical structure for biochemical analysis, diagnostics and therapy
US20080226723A1 (en) * 2002-07-05 2008-09-18 Celonova Biosciences, Inc. Loadable Polymeric Particles for Therapeutic Use in Erectile Dysfunction and Methods of Preparing and Using the Same
AU2003269904A1 (en) * 2002-07-10 2004-01-23 The Ohio State University Research Foundation Antigen-polymer compositions
US20040161470A1 (en) * 2002-11-22 2004-08-19 Alexander Andrianov Preparation of polyphosphazene microspheres
US20040131631A1 (en) * 2002-11-22 2004-07-08 Alexander Andrianov Polyphosphazene immunostimulants
ITMI20031617A1 (en) * 2003-08-06 2005-02-07 Fond Carlo E Dirce Callerio Onlus MICROCAPSULE WITH DOUBLE LAYER OF USE POLISACCHARIDES
ATE449161T1 (en) * 2004-03-04 2009-12-15 Leukocare Ag LEUKOCYTE STIMULATION MATRIX
CA2581775A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
US20060193820A1 (en) * 2005-02-18 2006-08-31 Andrianov Alexander K Immunostimulating polyphosphazene compounds
US7977314B2 (en) 2005-12-02 2011-07-12 Amorfix Life Sciences Limited Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
KR100784485B1 (en) * 2006-01-18 2007-12-11 한국과학기술연구원 Biodegradable and thermosensitive polyorganophosphazene hydrogel, preparation method thereof and use thereof
KR101083471B1 (en) 2006-10-10 2011-11-16 셀로노바 바이오사이언시즈, 인코포레이티드 Bioprosthetic Heart Valve with Polyphosphazene
JP2010528893A (en) * 2007-05-18 2010-08-26 ハイアー ディメンション マテリアルズ,インコーポレイティド Flame-retardant and heat-insulating flexible material provided with an expansion protection plate, and method for producing the same
EP2173431A4 (en) * 2007-07-09 2013-06-12 Apogee Technology Inc Immunostimulating polyphosphazene compounds for intradermal immunization
US8597663B2 (en) 2007-09-11 2013-12-03 University Of Guelph Polysaccharide immunogens from Clostridium difficile
PT2198007T (en) 2007-09-14 2018-01-29 Sanofi Pasteur Biologics Llc Pharmaceutical compositions containing clostridium difficile toxoids a and b
US9416165B2 (en) 2007-10-26 2016-08-16 The Regents Of The University Of California Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
US20090111763A1 (en) * 2007-10-26 2009-04-30 Celonova Biosciences, Inc. Loadable polymeric particles for bone augmentation and methods of preparing and using the same
US20090110738A1 (en) * 2007-10-26 2009-04-30 Celonova Biosciences, Inc. Loadable Polymeric Particles for Cosmetic and Reconstructive Tissue Augmentation Applications and Methods of Preparing and Using the Same
US20090110730A1 (en) * 2007-10-30 2009-04-30 Celonova Biosciences, Inc. Loadable Polymeric Particles for Marking or Masking Individuals and Methods of Preparing and Using the Same
US20090110731A1 (en) * 2007-10-30 2009-04-30 Celonova Biosciences, Inc. Loadable Polymeric Microparticles for Therapeutic Use in Alopecia and Methods of Preparing and Using the Same
EP2421505A4 (en) * 2009-04-22 2014-01-01 Univ Texas Hydrogels for combinatorial delivery of immune-modulating biomolecules
JP5640079B2 (en) 2009-05-18 2014-12-10 シグモイド・ファーマ・リミテッドSigmoid Pharma Limited Oil droplet-containing composition
CN107582526A (en) 2009-08-12 2018-01-16 希格默伊德药业有限公司 Immune regulation composite comprising polymer substrate and oil phase
EP2498763A4 (en) 2009-11-09 2015-10-07 Spotlight Technology Partners Llc Polysaccharide based hydrogels
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
CN102219911B (en) * 2011-04-28 2012-10-17 北京化工大学 Injectable polyphosphazene/gelatin composite hydrogel and preparation method thereof
CA2861565A1 (en) * 2012-01-20 2013-07-25 Fernando Thome Kreutz Autologous cancer cell vaccine
EP2841098A4 (en) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanoparticles for treatment of allergy
GB201212010D0 (en) * 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN103110941B (en) * 2012-10-09 2014-09-03 江苏康为世纪生物科技有限公司 Novel immunological adjuvant and quick immunization scheme
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2966801A1 (en) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprising cyclosporin
KR101762003B1 (en) 2015-07-16 2017-07-26 연세대학교 산학협력단 Delivery carrier of oral virus vaccine
US11472927B2 (en) 2015-11-18 2022-10-18 University Of Maryland, College Park Polyphosphazenes, methods of making, and uses thereof
WO2018009672A1 (en) * 2016-07-06 2018-01-11 University Of Maryland, College Park Polyphosphazene polyelectrolytes and uses thereof
WO2019173871A1 (en) * 2018-03-13 2019-09-19 Capsular Technologies Pty Ltd Vaccine composition
WO2020145489A1 (en) * 2019-01-10 2020-07-16 서울대학교산학협력단 Oral vaccine composition containing hydrogel-encapsulated inactivated cells
IT201900007060A1 (en) 2019-05-21 2020-11-21 St Superiore Di Sanita Engineered tumor cells and their uses
US20200383932A1 (en) * 2019-06-05 2020-12-10 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
IT201900012540A1 (en) 2019-07-22 2021-01-22 Humanitas Mirasole Spa CHI3L1 inhibitors and their uses

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3893980A (en) * 1974-03-29 1975-07-08 Pennsylvania Res Corp Poly(amino acid alkyl ester phosphazenes)
US4026839A (en) * 1976-08-30 1977-05-31 Armstrong Cork Company Polyphosphazene polymer/silicone rubber blends and foams therefrom
US4055520A (en) * 1976-07-14 1977-10-25 Armstrong Cork Company Polyphosphazene blends
US4094971A (en) * 1975-08-29 1978-06-13 Agence Nationale De Valorisation De La Recherche Immunological adjuvant agents active in aqueous solution
US4209014A (en) * 1977-12-12 1980-06-24 Canadian Patents And Development Limited Dispensing device for medicaments
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4440921A (en) * 1982-06-21 1984-04-03 Research Corporation Coupling of polyorganophosphazenes to carboxylic acid
US4451647A (en) * 1982-06-21 1984-05-29 Research Corporation Heparinized polyorganophosphazenes
US4495174A (en) * 1982-06-21 1985-01-22 Research Corporation Anesthetic polyorganophosphazenes
EP0168277A1 (en) * 1984-06-06 1986-01-15 Merck & Co. Inc. Poly(orthoester)polymers containing pendant acid functionalities and labile backbone bonds
US4636387A (en) * 1982-06-21 1987-01-13 Research Corporation Anesthetic polyorganophosphazenes
US4880622A (en) * 1986-05-20 1989-11-14 Research Corporation Technologies, Inc. Water-soluble phosphazene polymers having pharmacological applications
US4946938A (en) * 1989-08-01 1990-08-07 The University Of Pittsburgh A process for the catalytic synthesis of polyphosphazenes
US4975280A (en) * 1989-01-23 1990-12-04 Ethyl Corporation Bioerodable sustained release implants
US5053451A (en) * 1990-01-19 1991-10-01 The Pennsylvania Research Corporation Ionically cross-linkable polyphosphazene: poly(bis(carboxylatophenoxy) phosphazene) and its hydrogels and membranes
US5104947A (en) * 1989-08-07 1992-04-14 Ethyl Corporation Polyphosphazenes and their synthesis
WO1992005778A1 (en) * 1990-10-05 1992-04-16 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5109026A (en) * 1986-08-15 1992-04-28 Commonwealth Scientific And Industrial Research Organization 2-component immunoadjuvant
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
EP0539571A1 (en) * 1991-05-14 1993-05-05 Blue Sky Research, Inc. Dynamic shearing interferometer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3893980A (en) * 1974-03-29 1975-07-08 Pennsylvania Res Corp Poly(amino acid alkyl ester phosphazenes)
US4094971A (en) * 1975-08-29 1978-06-13 Agence Nationale De Valorisation De La Recherche Immunological adjuvant agents active in aqueous solution
US4055520A (en) * 1976-07-14 1977-10-25 Armstrong Cork Company Polyphosphazene blends
US4073824A (en) * 1976-07-14 1978-02-14 Armstrong Cork Company Polyphosphazene blends
US4026839A (en) * 1976-08-30 1977-05-31 Armstrong Cork Company Polyphosphazene polymer/silicone rubber blends and foams therefrom
US4073825A (en) * 1976-08-30 1978-02-14 Armstrong Cork Company Polyphosphazene polymer/silicone rubber blends and foams therefrom
US4209014A (en) * 1977-12-12 1980-06-24 Canadian Patents And Development Limited Dispensing device for medicaments
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4495174A (en) * 1982-06-21 1985-01-22 Research Corporation Anesthetic polyorganophosphazenes
US4451647A (en) * 1982-06-21 1984-05-29 Research Corporation Heparinized polyorganophosphazenes
US4440921A (en) * 1982-06-21 1984-04-03 Research Corporation Coupling of polyorganophosphazenes to carboxylic acid
US4636387A (en) * 1982-06-21 1987-01-13 Research Corporation Anesthetic polyorganophosphazenes
EP0168277A1 (en) * 1984-06-06 1986-01-15 Merck & Co. Inc. Poly(orthoester)polymers containing pendant acid functionalities and labile backbone bonds
US4880622A (en) * 1986-05-20 1989-11-14 Research Corporation Technologies, Inc. Water-soluble phosphazene polymers having pharmacological applications
US5109026A (en) * 1986-08-15 1992-04-28 Commonwealth Scientific And Industrial Research Organization 2-component immunoadjuvant
US4975280A (en) * 1989-01-23 1990-12-04 Ethyl Corporation Bioerodable sustained release implants
US4946938A (en) * 1989-08-01 1990-08-07 The University Of Pittsburgh A process for the catalytic synthesis of polyphosphazenes
US5104947A (en) * 1989-08-07 1992-04-14 Ethyl Corporation Polyphosphazenes and their synthesis
US5053451A (en) * 1990-01-19 1991-10-01 The Pennsylvania Research Corporation Ionically cross-linkable polyphosphazene: poly(bis(carboxylatophenoxy) phosphazene) and its hydrogels and membranes
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
WO1992005778A1 (en) * 1990-10-05 1992-04-16 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
EP0539571A1 (en) * 1991-05-14 1993-05-05 Blue Sky Research, Inc. Dynamic shearing interferometer

Non-Patent Citations (148)

* Cited by examiner, † Cited by third party
Title
Allcock et al (1983) 16(4 and 9):715 719 and 1401 1406. *
Allcock et al (1983) 16(4 and 9):715-719 and 1401-1406.
Allcock, H. R. et al., "Activity of urea amidohydrolase immobilized within poly[di(methoxyethoxyethoxy)phosphazene] hydrogels", Biomaterials, 00(0) (1994).
Allcock, H. R. et al., "Alkanesulfonation of Cyclic and High Polymeric Phosphazenes", Macromolecules, 26:5512-5519 (1993).
Allcock, H. R. et al., "Coupling of Cyclic and High-Polymeric [(Aminoaryl)oxy]phosphazenes to Carboxylic Acids: Prototypes for Bioactive Polymers", Macromolecules, 15:693-696 (1982).
Allcock, H. R. et al., Activity of urea amidohydrolase immobilized within poly di(methoxyethoxyethoxy)phosphazene hydrogels , Biomaterials , 00(0) (1994). *
Allcock, H. R. et al., Alkanesulfonation of Cyclic and High Polymeric Phosphazenes , Macromolecules , 26:5512 5519 (1993). *
Allcock, H. R. et al., Coupling of Cyclic and High Polymeric (Aminoaryl)oxy phosphazenes to Carboxylic Acids: Prototypes for Bioactive Polymers , Macromolecules , 15:693 696 (1982). *
Allcock, H. R., "A New Approach to Polymer Chemistry: Organometallic and Bioactive Phosphazenes", Journal of Polymer Science: Polymer Symposium, 70:71-77 (1983).
Allcock, H. R., "Chemical Synthesis at the Boundary between Polymer Chemistry and Inorganic Materials", The Chemist, 10-16 (Jan. 1990).
Allcock, H. R., "Cyclic and High-Polymeric Phosphazenes as Carrier Molecules for Carboranyl, Metallo, or Bioactive Side Groups", ALS Symp. Ser., 232:49-67 (1983).
Allcock, H. R., "Developments at the Interface of Inorganic, Organic and Polymer Chemistry", Chemical and Engineering News, 63:22-36 (1985).
Allcock, H. R., "Organometallic and Bioactive Cyclophosphazenes, and the Relationship to Inorganic Macromolecules", Phosphorus Sulfur, and Silica, 41:119-133 (1989).
Allcock, H. R., "Poly(organophosphazenes) Designed For Biomedical Uses", Organometallic Polymers, New York: Academic Press, pp. 283-288 (1978).
Allcock, H. R., "Polyphosphazenes as New Biomedical and Bioactive Materials", In Biodegradable Polymers as Drug Delivery Systems, eds. R. Langer and M. Chasin, Marcel Dekker: New York, pp. 163-193 (1990).
Allcock, H. R., "Polyphosphazenes", J. of Inorganic and Organometallic Polymers, 2(2):197-211 (1992).
Allcock, H. R., "Rational Design and Synthesis of New Polymeric Materials", Science, 255:1106-1112 (1992).
Allcock, H. R., "Tailored Design of New Polyphosphazenes with Special Properties", Progress in Pacific Polymer Science, ed. Y. Imanishi. Springer-Verlag Berlin Heidelberg, pp 89-100 (1992).
Allcock, H. R., "The Current State of the Art in the Synthesis of Inorganic Organometallic Polymers", Inorganic and Organometallic Polymers with Special Properties, ed. Laine, Kluwer Academic Publishers, pp. 43-62. (1992).
Allcock, H. R., A New Approach to Polymer Chemistry: Organometallic and Bioactive Phosphazenes , Journal of Polymer Science: Polymer Symposium, 70:71 77 (1983). *
Allcock, H. R., Chemical Synthesis at the Boundary between Polymer Chemistry and Inorganic Materials , The Chemist , 10 16 (Jan. 1990). *
Allcock, H. R., Cyclic and High Polymeric Phosphazenes as Carrier Molecules for Carboranyl, Metallo, or Bioactive Side Groups , ALS Symp. Ser. , 232:49 67 (1983). *
Allcock, H. R., Developments at the Interface of Inorganic, Organic and Polymer Chemistry , Chemical and Engineering News , 63:22 36 (1985). *
Allcock, H. R., et al, "Organosiloxyphosphazene Polymers: Synthesis via Aminosiloxane Reagents", Macromolecules, 23,:1626-1635 (1990).
Allcock, H. R., et al, "Poly(organophosphazenes) with Oligopeptides as Side Groups: Prospective Biomaterials", Macromolecules, 24:993-999 (1991).
Allcock, H. R., et al, Organosiloxyphosphazene Polymers: Synthesis via Aminosiloxane Reagents , Macromolecules , 23,:1626 1635 (1990). *
Allcock, H. R., et al, Poly(organophosphazenes) with Oligopeptides as Side Groups: Prospective Biomaterials , Macromolecules, 24:993 999 (1991). *
Allcock, H. R., et al. "Effects of Organic Side Group Structures on the Properties of Poly(organophosphzenes)", Macromolecules, 21:323-334 (1988).
Allcock, H. R., et al. "Phosphonitrilic Compounds, XV. High Molecular Weight Poly[bis(amino)phosphazenes] and Mixed-Substitunent Poly(aminophosphazenes)", Inorganic Chemistry, 11(7):2584-2590 (1972).
Allcock, H. R., et al. "Preparation and Characterization of Poly(organophosphazene) Blends", Material, 4:1182-1187 (1992).
Allcock, H. R., et al. Effects of Organic Side Group Structures on the Properties of Poly(organophosphzenes) , Macromolecules , 21:323 334 (1988). *
Allcock, H. R., et al. Phosphonitrilic Compounds, XV. High Molecular Weight Poly bis(amino)phosphazenes and Mixed Substitunent Poly(aminophosphazenes) , Inorganic Chemistry , 11(7):2584 2590 (1972). *
Allcock, H. R., et al. Preparation and Characterization of Poly(organophosphazene) Blends , Material , 4:1182 1187 (1992). *
Allcock, H. R., et al., "Amphiphilic polyphosphazenes as membrane materials: influence of side group on radiation crosslinking", Biomaterials, 9:500-508 (1988).
Allcock, H. R., et al., "An Ionically Cross-Linkable Polyphosphazene: Poly[bis(carboxylatophenoxy)phosphazene] and Its Hydrogels and Membranes", Macromolecules, 22:75-79 (1989).
Allcock, H. R., et al., "Antibacterial Activity and Mutagenicity Studies of Water-Soluble Phosphazene High Polymers", Biomaterials, 13(12):857-862 (1992).
Allcock, H. R., et al., "Covalent Linkage of Proteins to Surface-Modified Poly(organophosphazenes): Immobilization of Glucose-6-Phosphate Dehydrogenase and Trypsin", Macromolecules, 19:1502-1508 (1986).
Allcock, H. R., et al., "Diazo Coupling Reactions with Poly(organophosphazenes)", Macromolecules, 14:1622-1625 (1981).
Allcock, H. R., et al., "Glyceryl Polyphosphazenes: Synthesis, Properties and Hydrolysis", Macromolecules, 21:1980-1985 (1988).
Allcock, H. R., et al., "Hydrolysis Pathways for Aminophosphazenes", Inorg. Chem., 21:515-521 (1982).
Allcock, H. R., et al., "Hydrophilic Polyphosphazenes as Hydrogels: Radiation Cross-linking and Hydrogel Characteristics of Poly[bis(methoxyethoxyethoxy)phosphazene]", Biomaterials, 9:509-513 (1988).
Allcock, H. R., et al., "Organosilicon Derivatives of Cyclic and High Polymeric Phosphazenes", J. Organometallic Chemistry, 341:231-239 (1988).
Allcock, H. R., et al., "Organosilylphosphazene Oligomers and Polymers: Synthesis via (Lithioaryloxy)phosphazenes", Macromolecules, 22:3571-3578 (1989).
Allcock, H. R., et al., "Oxidation of Poly[bis(4-methylphenoxy)phosphazene] Surfaces and Chemistry of the Surface Carboxylic Acid Groups", Materials, 4:769-775 (1992).
Allcock, H. R., et al., "Phosphazene High Polymers with Bioactive Substituent Groups; Prospective Anesthetic Aminophosphazenes", Macromolecules, 15(3):689-693 (1982).
Allcock, H. R., et al., "Poly(organophosphazenes) with Azoxybenzene Side Groups, Synthesis and Morphology", Macromolecules, 24:2841-2845 (1991).
Allcock, H. R., et al., "Poly(organophosphazenes) with Poly(alkyl ether) Side Groups: A Study of Their Water Solubility and the Swelling Characteristics of Their Hydrogels", Macromolecules, 25:5573-5577 (1992).
Allcock, H. R., et al., "Polyphosphazene-Organic Polymer Interpenetrating Polymer Networks", Materials, 4:1188-1192 (1992).
Allcock, H. R., et al., "Polyphosphazenes with Etheric Side Groups: Prospective Biomedical and Solid Electrolyte Polymers", Macromolecules, 19:1508-1512 (1986).
Allcock, H. R., et al., "Polyphosphazenes with Glucosyl and Methylamino, Trifluoroethoxy, Phenoxy, or (Methoxyethoxy)ethoxy Side Groups", Macromolecules, 24:23-34 (1991).
Allcock, H. R., et al., "Ring-Opening Polymerization of Methylsilane- and Methylsiloxane-Substituted Cyclotriphosphazenes", Macromolecules, 21:1-10 (1988).
Allcock, H. R., et al., "Schiff Base Coupling of Cyclic and High-Polymeric Phosphazenes to Aldehydes and Amines: Chemotherapeutic Models", Macromolecules, 14:1615-1622 (1981).
Allcock, H. R., et al., "Surface Reaction of Poly[bis(trifluoroethoxy)phosphazene] Films by Basic Hydrolysis", Materials, 3:442-449 (1991).
Allcock, H. R., et al., "Synthesis and Properties of High Polymeric Phosphazenes with (Trimethylsilyl)methyl Side Groups", Macromolecules, 26:764-771 (1993).
Allcock, H. R., et al., "Synthesis and Reactivity of Cyclotriphosphazenes Bearing Reactive Silane Functionalities: Novel Derivatives via Hydrosilylation Reactions", Organometallics, 10:3819-3825 (1991).
Allcock, H. R., et al., "Synthesis of High Polymeric Alkoxy- and Aryloxyphosphonitriles", Journal of the American Chemical Society, 87(18):4216-4217 (1965).
Allcock, H. R., et al., "Synthesis of New Polyphosphazene Elastomers", Macromolecules, 23:3873-3877 (1990).
Allcock, H. R., et al., "Synthesis of Poly[(amino acid alkyl ester)phosphazenes]", Macromolecules, 10(4):824-830 (1977).
Allcock, H. R., et al., "Synthesis of Polyphosphazenes Bearing Geminal (Trimethylsilyl)methylene and Alkyl or Phenyl Side Groups", Macromolecules, 22:1534-1539 (1989).
Allcock, H. R., et al., "Synthesis of Polyphosphazenes with Isothiocyanato, Thiourethane, and Thiourea Side Groups", Macromolecules, 24:2852-2857 (1991).
Allcock, H. R., et al., "Thin-Layer Grafts of Poly[bis((methoxyethoxy) ethoxy)phosphazene] on Organic Polymer Surfaces," 4:775-780 (1992).
Allcock, H. R., et al., Amphiphilic polyphosphazenes as membrane materials: influence of side group on radiation crosslinking , Biomaterials , 9:500 508 (1988). *
Allcock, H. R., et al., An Ionically Cross Linkable Polyphosphazene: Poly bis(carboxylatophenoxy)phosphazene and Its Hydrogels and Membranes , Macromolecules, 22:75 79 (1989). *
Allcock, H. R., et al., Antibacterial Activity and Mutagenicity Studies of Water Soluble Phosphazene High Polymers , Biomaterials , 13(12):857 862 (1992). *
Allcock, H. R., et al., Covalent Linkage of Proteins to Surface Modified Poly(organophosphazenes): Immobilization of Glucose 6 Phosphate Dehydrogenase and Trypsin , Macromolecules , 19:1502 1508 (1986). *
Allcock, H. R., et al., Diazo Coupling Reactions with Poly(organophosphazenes) , Macromolecules , 14:1622 1625 (1981). *
Allcock, H. R., et al., Glyceryl Polyphosphazenes: Synthesis, Properties and Hydrolysis , Macromolecules , 21:1980 1985 (1988). *
Allcock, H. R., et al., Hydrolysis Pathways for Aminophosphazenes , Inorg. Chem. , 21:515 521 (1982). *
Allcock, H. R., et al., Hydrophilic Polyphosphazenes as Hydrogels: Radiation Cross linking and Hydrogel Characteristics of Poly bis(methoxyethoxyethoxy)phosphazene , Biomaterials , 9:509 513 (1988). *
Allcock, H. R., et al., Organosilicon Derivatives of Cyclic and High Polymeric Phosphazenes , J. Organometallic Chemistry , 341:231 239 (1988). *
Allcock, H. R., et al., Organosilylphosphazene Oligomers and Polymers: Synthesis via (Lithioaryloxy)phosphazenes , Macromolecules , 22:3571 3578 (1989). *
Allcock, H. R., et al., Oxidation of Poly bis(4 methylphenoxy)phosphazene Surfaces and Chemistry of the Surface Carboxylic Acid Groups , Materials , 4:769 775 (1992). *
Allcock, H. R., et al., Phosphazene High Polymers with Bioactive Substituent Groups; Prospective Anesthetic Aminophosphazenes , Macromolecules , 15(3):689 693 (1982). *
Allcock, H. R., et al., Poly (aryloxy)carbophosphazenes : Synthesis, Properties, and Thermal Transition Behavior, Macromolecules, 24:2024 2028 (1991). *
Allcock, H. R., et al., Poly(organophosphazenes) with Azoxybenzene Side Groups, Synthesis and Morphology , Macromolecules , 24:2841 2845 (1991). *
Allcock, H. R., et al., Poly(organophosphazenes) with Poly(alkyl ether) Side Groups: A Study of Their Water Solubility and the Swelling Characteristics of Their Hydrogels , Macromolecules , 25:5573 5577 (1992). *
Allcock, H. R., et al., Poly[(aryloxy)carbophosphazenes]: Synthesis, Properties, and Thermal Transition Behavior, Macromolecules, 24:2024-2028 (1991).
Allcock, H. R., et al., Polyphosphazene Organic Polymer Interpenetrating Polymer Networks , Materials , 4:1188 1192 (1992). *
Allcock, H. R., et al., Polyphosphazenes with Etheric Side Groups: Prospective Biomedical and Solid Electrolyte Polymers , Macromolecules , 19:1508 1512 (1986). *
Allcock, H. R., et al., Polyphosphazenes with Glucosyl and Methylamino, Trifluoroethoxy, Phenoxy, or (Methoxyethoxy)ethoxy Side Groups , Macromolecules , 24:23 34 (1991). *
Allcock, H. R., et al., Ring Opening Polymerization of Methylsilane and Methylsiloxane Substituted Cyclotriphosphazenes , Macromolecules , 21:1 10 (1988). *
Allcock, H. R., et al., Schiff Base Coupling of Cyclic and High Polymeric Phosphazenes to Aldehydes and Amines: Chemotherapeutic Models , Macromolecules , 14:1615 1622 (1981). *
Allcock, H. R., et al., Surface Reaction of Poly bis(trifluoroethoxy)phosphazene Films by Basic Hydrolysis , Materials , 3:442 449 (1991). *
Allcock, H. R., et al., Synthesis and Properties of High Polymeric Phosphazenes with (Trimethylsilyl)methyl Side Groups , Macromolecules , 26:764 771 (1993). *
Allcock, H. R., et al., Synthesis and Reactivity of Cyclotriphosphazenes Bearing Reactive Silane Functionalities: Novel Derivatives via Hydrosilylation Reactions , Organometallics , 10:3819 3825 (1991). *
Allcock, H. R., et al., Synthesis of High Polymeric Alkoxy and Aryloxyphosphonitriles , Journal of the American Chemical Society , 87(18):4216 4217 (1965). *
Allcock, H. R., et al., Synthesis of New Polyphosphazene Elastomers , Macromolecules , 23:3873 3877 (1990). *
Allcock, H. R., et al., Synthesis of Poly (amino acid alkyl ester)phosphazenes , Macromolecules , 10(4):824 830 (1977). *
Allcock, H. R., et al., Synthesis of Polyphosphazenes Bearing Geminal (Trimethylsilyl)methylene and Alkyl or Phenyl Side Groups , Macromolecules , 22:1534 1539 (1989). *
Allcock, H. R., et al., Synthesis of Polyphosphazenes with Isothiocyanato, Thiourethane, and Thiourea Side Groups , Macromolecules , 24:2852 2857 (1991). *
Allcock, H. R., et al., Thin Layer Grafts of Poly bis((methoxyethoxy) ethoxy)phosphazene on Organic Polymer Surfaces, 4:775 780 (1992). *
Allcock, H. R., Organometallic and Bioactive Cyclophosphazenes, and the Relationship to Inorganic Macromolecules , Phosphorus Sulfur, and Silica , 41:119 133 (1989). *
Allcock, H. R., Poly(organophosphazenes) Designed For Biomedical Uses , Organometallic Polymers , New York: Academic Press, pp. 283 288 (1978). *
Allcock, H. R., Polyphosphazenes , J. of Inorganic and Organometallic Polymers , 2(2):197 211 (1992). *
Allcock, H. R., Polyphosphazenes as New Biomedical and Bioactive Materials , In Biodegradable Polymers as Drug Delivery Systems , eds. R. Langer and M. Chasin, Marcel Dekker: New York, pp. 163 193 (1990). *
Allcock, H. R., Rational Design and Synthesis of New Polymeric Materials , Science , 255:1106 1112 (1992). *
Allcock, H. R., Tailored Design of New Polyphosphazenes with Special Properties , Progress in Pacific Polymer Science , ed. Y. Imanishi. Springer Verlag Berlin Heidelberg, pp 89 100 (1992). *
Allcock, H. R., The Current State of the Art in the Synthesis of Inorganic Organometallic Polymers , Inorganic and Organometallic Polymers with Special Properties , ed. Laine, Kluwer Academic Publishers, pp. 43 62. (1992). *
Allcock, H. R.., et al., "Functionalization of the Surface of Poly[bis(trifluoroethoxy)phosphazene] by Reactions with Alkoxide Nucleophiles", Materials, 3:450-454 (1991).
Allcock, H. R.., et al., "Synthesis of Poly[bis(phosphazo)phosphazenes] Bearing Aryloxy and Alkoxy Side Groups", Macromolecules, 25:2802-2810 (1992).
Allcock, H. R.., et al., Functionalization of the Surface of Poly bis(trifluoroethoxy)phosphazene by Reactions with Alkoxide Nucleophiles , Materials , 3:450 454 (1991). *
Allcock, H. R.., et al., Synthesis of Poly bis(phosphazo)phosphazenes Bearing Aryloxy and Alkoxy Side Groups , Macromolecules , 25:2802 2810 (1992). *
Allison et al in Vaccines: New Approaches to immunological problems ed by R. W. Ellis, 1992, Butterworth Heineman; pp. 431 449. *
Allison et al in Vaccines: New Approaches to immunological problems ed by R. W. Ellis, 1992, Butterworth-Heineman; pp. 431-449.
Coltrain, B. K., et al., "Polyphosphazene Molecular Composites, 1. In Situ Polymerization of Tetraethoxysilane", Chem. Mater., 4:358-364 (1992).
Coltrain, B. K., et al., Polyphosphazene Molecular Composites, 1. In Situ Polymerization of Tetraethoxysilane , Chem. Mater. , 4:358 364 (1992). *
Crommen et al (1993) J. Controlled Rel. 24:167 180. *
Crommen et al (1993) J. Controlled Rel. 24:167-180.
Eldridge, J. H., et al., "Biodegradable Micropheres: Vaccine Delivery System for Oral Immunization", Microbiology and Immunology, 146:59-66 (1989). Grolleman, et al., J. Controlled Release, 3:143 (1986)*.
Eldridge, J. H., et al., Biodegradable Micropheres: Vaccine Delivery System for Oral Immunization , Microbiology and Immunology , 146:59 66 (1989). Grolleman, et al., J. Controlled Release , 3:143 (1986)*. *
Goedemaed et al (1991) J. Controlled Release 170:245 258. *
Goedemaed et al (1991) J. Controlled Release 170:245-258.
Grolleman et al (1986) J. Controlled Rease 4:119 131. *
Grolleman et al (1986) J. Controlled Rease 4:119-131.
Grolleman, C. W. J., et al., "Studies on a Bioerodible Drug Carrier System Based on Polyphosphazene." J. Cont. Release 3:143-154 (1986).
Grolleman, C. W. J., et al., Studies on a Bioerodible Drug Carrier System Based on Polyphosphazene. J. Cont. Release 3:143 154 (1986). *
Gupta et al (1993) Vaccines 11(3): 293 306. *
Gupta et al (1993) Vaccines 11(3): 293-306.
Landry, Christine, et al., "Novel Miscible Blends of Etheric Polyphosphazenes with Acidic Polymers", Macromolecules, 26:35-46 (1993).
Landry, Christine, et al., Novel Miscible Blends of Etheric Polyphosphazenes with Acidic Polymers , Macromolecules , 26:35 46 (1993). *
Laurencin, C. T., et al., "Controlled release using a new bioerodible polyphosphazene matrix system", Journal of Biomedical Materials Research, 21:1231-1246 (1987).
Laurencin, C. T., et al., "Use of Polyphosphazenes for Skeletal Tissue Regeneration", J. Biomed. Mater. Res., 27:963-973 (1993).
Laurencin, C. T., et al., Controlled release using a new bioerodible polyphosphazene matrix system , Journal of Biomedical Materials Research , 21:1231 1246 (1987). *
Laurencin, C. T., et al., Use of Polyphosphazenes for Skeletal Tissue Regeneration , J. Biomed. Mater. Res. , 27:963 973 (1993). *
Mark, J. E., et al., "Polyphosphazenes", Inorganic Polymers, ed. Prentice-Hall, pp. 61-139 (1992).
Mark, J. E., et al., Polyphosphazenes , Inorganic Polymers , ed. Prentice Hall, pp. 61 139 (1992). *
Neenan, T. X., et al., "Synthesis of a heparinized poly(organophosphazene)", Biomaterials, 3:78-80 (1982).
Neenan, T. X., et al., Synthesis of a heparinized poly(organophosphazene) , Biomaterials , 3:78 80 (1982). *
Ngo, D. C., et al., "Poly(phosphazophosphazenes): A New Class of Inorganic Polymers with Short-Chain Branching", Journal of the American Chemical Society, pp. 113-114 (1991).
Ngo, D. C., et al., Poly(phosphazophosphazenes): A New Class of Inorganic Polymers with Short Chain Branching , Journal of the American Chemical Society , pp. 113 114 (1991). *
Novak, M., et al., "Murine model for evaluation of protective immunity to influenza virus", Vaccine, 11(1):55-60 (1993).
Novak, M., et al., Murine model for evaluation of protective immunity to influenza virus , Vaccine , 11(1):55 60 (1993). *
Payne, L. G., et al., "Xenobiotic Polymers as Vaccine Vehicles", 7th International Congress of Mucosal Immunology, Prague, Czechoslovakia, Aug. 16-20, 1992.
Payne, L. G., et al., Xenobiotic Polymers as Vaccine Vehicles , 7th International Congress of Mucosal Immunology , Prague, Czechoslovakia, Aug. 16 20, 1992. *
Petrov, et al., Jhurnal Vses, Khim. Ob va im. D. I. Mendeleeva , 33:22 42 (1988)*. *
Petrov, et al., Jhurnal Vses, Khim. Ob-va im. D. I. Mendeleeva, 33:22-42 (1988)*.
Petrov, et al., Sov. Med. Rev. D. Immunol ., 4:1 113 (1992)*. *
Petrov, et al., Sov. Med. Rev. D. Immunol., 4:1-113 (1992)*.
Petrov. et al., Zhurnal Vsesovuznogo Khimicheskogo Obshchestva im. D. I. Mendeleeva , 33:22 42 (1988). *
Petrov. et al., Zhurnal Vsesovuznogo Khimicheskogo Obshchestva im. D. I. Mendeleeva, 33:22-42 (1988).
Shapiro, A., et al., "Efficacies of Vaccines containing Alginate Adjuvant", J. appl. Bact., 30(2):304-311 (1967).
Shapiro, A., et al., Efficacies of Vaccines containing Alginate Adjuvant , J. appl. Bact. , 30(2):304 311 (1967). *
Shechmeister, I. L., et al., "Use of Sodium Alginate Adjuvant in Immunization Against Equine Influenza", Am. J. Vet. Res., 28(126):1373-1378 (1967).
Shechmeister, I. L., et al., Use of Sodium Alginate Adjuvant in Immunization Against Equine Influenza , Am. J. Vet. Res., 28(126):1373 1378 (1967). *
Visscher, K. B., et al., "Synthesis and Characterization of Polyphosphazene Interpenetrating Polymer Networks", Polymeric Materials Science & Engineering, 65:3-4 (1991).
Visscher, K. B., et al., "Synthesis and Properties of Polyphosphazene Interpenetrating Polymer Networks", Macromolecules, 23(22):4885-4886 (1990).
Visscher, K. B., et al., Synthesis and Characterization of Polyphosphazene Interpenetrating Polymer Networks , Polymeric Materials Science & Engineering , 65:3 4 (1991). *
Visscher, K. B., et al., Synthesis and Properties of Polyphosphazene Interpenetrating Polymer Networks , Macromolecules , 23(22):4885 4886 (1990). *

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096403A1 (en) * 1995-05-15 2004-05-20 Mannkind Corporation Method for drug delivery to the pulmonary system
US8394414B2 (en) 1995-05-15 2013-03-12 Mannkind Corporation Method for drug delivery to the pulmonary system
US5898062A (en) * 1996-04-10 1999-04-27 The Penn State Research Foundation Poly (organophosphazene) hydrogels
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
US20030092665A1 (en) * 1997-04-30 2003-05-15 Compans Richard W. Methods and compositions for administering DNA to mucosal surfaces
US6077916A (en) * 1997-06-04 2000-06-20 The Penn State Research Foundation Biodegradable mixtures of polyphoshazene and other polymers
US6207171B1 (en) * 1998-03-27 2001-03-27 Avant Immunotherapeutics, Inc. Polyphosphazene microspheres
WO2000025815A1 (en) * 1998-10-30 2000-05-11 Avant Immunotherapeutics, Inc. Novel immunoadjuvants
US7648960B2 (en) 1999-06-29 2010-01-19 Mannkind Corporation Method for delivery of monomeric or dimeric insulin complexed to diketopiperazine microparticles
US7943178B2 (en) 1999-06-29 2011-05-17 Mannkind Corporation Methods and compositions for delivering peptides
US20040077528A1 (en) * 1999-06-29 2004-04-22 Mannkind Corporation Purification and stabilization of peptide and protein pharmaceutical agents
US20110105391A1 (en) * 1999-06-29 2011-05-05 Mannkind Corporation Methods and Compositions for Delivering Peptides
US8389470B2 (en) 1999-06-29 2013-03-05 Mannkind Corporation Methods and compositions for delivering peptides
US20100086609A1 (en) * 1999-06-29 2010-04-08 Mannkind Corporation Methods and Compositions for Delivering Peptides
US9801925B2 (en) 1999-06-29 2017-10-31 Mannkind Corporation Potentiation of glucose elimination
US20070020191A1 (en) * 1999-06-29 2007-01-25 Mannkind Corporation Potentiation of glucose elimination
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6605237B2 (en) * 2000-06-29 2003-08-12 The Penn State Research Foundation Polyphosphazenes as gel polymer electrolytes
US9080146B2 (en) 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
WO2003046054A2 (en) * 2001-11-29 2003-06-05 Parallel Solutions, Inc. Copolymer libraries and production and use thereof
WO2003046054A3 (en) * 2001-11-29 2003-10-23 Parallel Solutions Inc Copolymer libraries and production and use thereof
US8084015B2 (en) 2002-02-14 2011-12-27 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20030165478A1 (en) * 2002-02-14 2003-09-04 Sokoll Kenneth K. Stabilized synthetic immunogen delivery system
US20040009897A1 (en) * 2002-02-14 2004-01-15 Sokoll Kenneth K. Stabilized synthetic immunogen delivery system
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US20050088617A1 (en) * 2003-10-27 2005-04-28 Jen-Chuen Hsieh Method and apparatus for visual drive control
US20050153874A1 (en) * 2004-01-12 2005-07-14 Mannkind Corporation Method of reducing serum proinsulin levels in type 2 diabetics
US20090192075A1 (en) * 2004-03-12 2009-07-30 Biodel Inc. Amylin Formulations
US8933023B2 (en) 2004-03-12 2015-01-13 Biodel Inc. Rapid acting injectable insulin compositions
US7074256B2 (en) * 2004-05-13 2006-07-11 Battelle Energy Alliance, Llc Phosphazene membranes for gas separations
US20060016331A1 (en) * 2004-05-13 2006-01-26 Stewart Frederick F Phosphazene membranes for gas separations
US9796688B2 (en) 2004-08-20 2017-10-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9346766B2 (en) 2004-08-20 2016-05-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US10130685B2 (en) 2004-08-23 2018-11-20 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US8318209B2 (en) 2004-10-25 2012-11-27 Celonova Biosciences Germany Gmbh Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US9114162B2 (en) 2004-10-25 2015-08-25 Celonova Biosciences, Inc. Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same
US11052050B2 (en) 2004-10-25 2021-07-06 Varian Medical Systems, Inc. Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US9597419B2 (en) 2004-10-25 2017-03-21 Boston Scientific Limited Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same
US9511153B2 (en) 2004-10-25 2016-12-06 Celonova Biosciences Germany Gmbh Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US20060088476A1 (en) * 2004-10-25 2006-04-27 Polyzenix Gmbh Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US10973770B2 (en) 2004-10-25 2021-04-13 Varian Medical Systems, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US9107850B2 (en) 2004-10-25 2015-08-18 Celonova Biosciences, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US8741454B2 (en) 2005-03-29 2014-06-03 Toyota Motor Engineering & Manufacturing North America, Inc. Proton exchange membrane for fuel cell
US20090004526A1 (en) * 2005-03-29 2009-01-01 Toyota Motor Engineering & Manufacturing North America, Inc. Proton exchange membrane for fuel cell
US10143655B2 (en) 2005-09-14 2018-12-04 Mannkind Corporation Method of drug formulation
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9717689B2 (en) 2005-09-14 2017-08-01 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9446001B2 (en) 2005-09-14 2016-09-20 Mannkind Corporation Increasing drug affinity for crystalline microparticle surfaces
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US10130581B2 (en) 2006-02-22 2018-11-20 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US7718609B2 (en) 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20090016935A1 (en) * 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US10201672B2 (en) 2008-06-13 2019-02-12 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9446133B2 (en) 2008-06-13 2016-09-20 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9511198B2 (en) 2008-06-13 2016-12-06 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9339615B2 (en) 2008-06-13 2016-05-17 Mannkind Corporation Dry powder inhaler and system for drug delivery
US10751488B2 (en) 2008-06-13 2020-08-25 Mannkind Corporation Dry powder inhaler and system for drug delivery
US10342938B2 (en) 2008-06-13 2019-07-09 Mannkind Corporation Dry powder drug delivery system
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US10675421B2 (en) 2008-06-20 2020-06-09 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US9408908B2 (en) 2008-10-16 2016-08-09 University Of Saskatchewan Combination adjuvant formulation
US9061001B2 (en) 2008-10-16 2015-06-23 University Of Saskatchewan Combination adjuvant formulation
WO2010043039A1 (en) 2008-10-16 2010-04-22 University Of Saskatchewan Combination adjuvant formulation
US20100239611A1 (en) * 2008-10-16 2010-09-23 Van Drunen Littel-Van Den Hurk Sylvia Combination adjuvant formulation
US9655850B2 (en) 2008-12-29 2017-05-23 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US10172850B2 (en) 2008-12-29 2019-01-08 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9252455B1 (en) * 2010-04-14 2016-02-02 Hrl Laboratories, Llc Lithium battery structures employing composite layers, and fabrication methods to produce composite layers
US10625034B2 (en) 2011-04-01 2020-04-21 Mannkind Corporation Blister package for pharmaceutical cartridges
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US10130709B2 (en) 2011-06-17 2018-11-20 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9610351B2 (en) 2011-10-24 2017-04-04 Mannkind Corporation Methods and compositions for treating pain
US10258664B2 (en) 2011-10-24 2019-04-16 Mannkind Corporation Methods and compositions for treating pain
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
WO2013116639A1 (en) 2012-02-01 2013-08-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Campylobacter immunogenic compositions and uses thereof
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US11905318B2 (en) 2015-11-09 2024-02-20 The University Of British Columbia Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
US11779629B2 (en) * 2016-11-09 2023-10-10 The University Of British Columbia Compositions comprising cyclic peptides derived from an A-beta peptide
US11397282B1 (en) 2018-06-29 2022-07-26 Hrl Laboratories, Llc Infrared-transparent polymer optics and methods of making and using the same

Also Published As

Publication number Publication date
DK0710117T3 (en) 2002-02-18
WO1995002415A1 (en) 1995-01-26
WO1995002628A1 (en) 1995-01-26
KR960703617A (en) 1996-08-31
SG46659A1 (en) 1998-02-20
KR960703620A (en) 1996-08-31
US5529777A (en) 1996-06-25
US5494673A (en) 1996-02-27
EP0710117B1 (en) 2001-10-24
KR100352336B1 (en) 2003-04-16
NZ269396A (en) 1999-09-29
ATE207505T1 (en) 2001-11-15
EP0710117A1 (en) 1996-05-08
DE69428795T2 (en) 2002-06-13
PT710117E (en) 2002-04-29
BR9407051A (en) 1996-08-13
DE69428795D1 (en) 2001-11-29
CA2166208A1 (en) 1995-01-26
JPH09500629A (en) 1997-01-21
ES2166376T3 (en) 2002-04-16
AU7326194A (en) 1995-02-13
AU691824B2 (en) 1998-05-28
KR100353496B1 (en) 2003-03-03
CA2166208C (en) 2010-04-20
CN1134265C (en) 2004-01-14
CN1128954A (en) 1996-08-14
EP0710117A4 (en) 1996-08-07

Similar Documents

Publication Publication Date Title
US5562909A (en) Phosphazene polyelectrolytes as immunoadjuvants
CA1323566C (en) Biodegradable polymeric drug delivery system with adjuvant activity
EP0946624B1 (en) Biodegradable targetable microparticle delivery system
US5855895A (en) Polyphosphazene polyelectrolyte immunoadjuvants
AU690567B2 (en) Hydrogel microencapsulated vaccines
US6207171B1 (en) Polyphosphazene microspheres
US9687546B2 (en) Immunostimulating polyphosphazene compounds
WO1995002416A9 (en) Hydrogel microencapsulated vaccines
Andrianov Water-soluble polyphosphazenes for biomedical applications
WO2001015727A2 (en) Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
AU738698B2 (en) Polyphosphazene polyelectrolyte immunoadjuvants
US20170258900A1 (en) Immunostimulating Polyphosphazene Compounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: VIRUS RESEARCH INSTITUTE, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDRIANOV, ALEXANDER K.;JENKINS, SHARON A.;PAYNE, LENDON G.;AND OTHERS;REEL/FRAME:006696/0829

Effective date: 19930910

Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LANGER, ROBERT S.;REEL/FRAME:006696/0827

Effective date: 19930910

AS Assignment

Owner name: PENN STATE RESEARCH FOUNDATION, PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALLCOCK, HARRY R.;VISSCHER, KARYN B.;REEL/FRAME:006756/0602

Effective date: 19930924

AS Assignment

Owner name: SILICON VALLEY BANK, CALIFORNIA

Free format text: SECURITY AGREEMENT;ASSIGNOR:VIRUS RESEARCH INSTITUTE, INC.;REEL/FRAME:007922/0303

Effective date: 19960402

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: VIRUS RESEARCH INSTITUTE, INC., MASSACHUSETTS

Free format text: SECURITY INTEREST;ASSIGNOR:SILICON VALLEY BANK;REEL/FRAME:012133/0483

Effective date: 19960422

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20041008